CA2453948C - Recombinant bovine pancreatic desoxyribonuclease i with high specific activity - Google Patents
Recombinant bovine pancreatic desoxyribonuclease i with high specific activity Download PDFInfo
- Publication number
- CA2453948C CA2453948C CA2453948A CA2453948A CA2453948C CA 2453948 C CA2453948 C CA 2453948C CA 2453948 A CA2453948 A CA 2453948A CA 2453948 A CA2453948 A CA 2453948A CA 2453948 C CA2453948 C CA 2453948C
- Authority
- CA
- Canada
- Prior art keywords
- protein
- bovine pancreatic
- seq
- desoxyribonuclease
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 230
- 102000016911 Deoxyribonucleases Human genes 0.000 title claims abstract description 207
- 108010053770 Deoxyribonucleases Proteins 0.000 title claims abstract description 207
- 229940109357 desoxyribonuclease Drugs 0.000 title claims abstract description 201
- 230000000694 effects Effects 0.000 title claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 267
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 249
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 127
- 238000000034 method Methods 0.000 claims abstract description 60
- 239000001963 growth medium Substances 0.000 claims abstract description 44
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 84
- 239000013598 vector Substances 0.000 claims description 71
- 239000002773 nucleotide Substances 0.000 claims description 69
- 125000003729 nucleotide group Chemical group 0.000 claims description 69
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 48
- 241000235058 Komagataella pastoris Species 0.000 claims description 41
- 238000003776 cleavage reaction Methods 0.000 claims description 21
- 230000007017 scission Effects 0.000 claims description 21
- 241000235648 Pichia Species 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 150000001768 cations Chemical class 0.000 claims description 18
- 108010087967 type I signal peptidase Proteins 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000013612 plasmid Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 7
- 230000001131 transforming effect Effects 0.000 claims description 7
- 210000004507 artificial chromosome Anatomy 0.000 claims description 6
- 241000320412 Ogataea angusta Species 0.000 claims description 5
- 210000000349 chromosome Anatomy 0.000 claims description 5
- 239000011535 reaction buffer Substances 0.000 claims description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 4
- 239000012536 storage buffer Substances 0.000 claims description 4
- 241000222124 [Candida] boidinii Species 0.000 claims description 3
- 241000222126 [Candida] glabrata Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 112
- 230000014509 gene expression Effects 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 42
- 150000007523 nucleic acids Chemical class 0.000 description 38
- 108020004707 nucleic acids Proteins 0.000 description 36
- 102000039446 nucleic acids Human genes 0.000 description 36
- 239000013604 expression vector Substances 0.000 description 33
- 239000012634 fragment Substances 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 230000009466 transformation Effects 0.000 description 23
- 239000003550 marker Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 230000001965 increasing effect Effects 0.000 description 17
- 108010025188 Alcohol oxidase Proteins 0.000 description 16
- 230000003248 secreting effect Effects 0.000 description 16
- 108091034117 Oligonucleotide Proteins 0.000 description 15
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 238000010369 molecular cloning Methods 0.000 description 12
- 108020004705 Codon Proteins 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- 239000012148 binding buffer Substances 0.000 description 8
- 101150038738 ble gene Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013519 translation Methods 0.000 description 8
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 230000008033 biological extinction Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000004923 pancreatic tissue Anatomy 0.000 description 6
- 108010051242 phenylalanylserine Proteins 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 238000000844 transformation Methods 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- 108010084455 Zeocin Proteins 0.000 description 5
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 5
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 108010017391 lysylvaline Proteins 0.000 description 5
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000600 sorbitol Substances 0.000 description 5
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 4
- DPNZTBKGAUAZQU-DLOVCJGASA-N Ala-Leu-His Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N DPNZTBKGAUAZQU-DLOVCJGASA-N 0.000 description 4
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 4
- LLUGJARLJCGLAR-CYDGBPFRSA-N Arg-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N LLUGJARLJCGLAR-CYDGBPFRSA-N 0.000 description 4
- HJRBIWRXULGMOA-ACZMJKKPSA-N Asn-Gln-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJRBIWRXULGMOA-ACZMJKKPSA-N 0.000 description 4
- SWTQDYFZVOJVLL-KKUMJFAQSA-N Asp-His-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC(=O)O)N)O SWTQDYFZVOJVLL-KKUMJFAQSA-N 0.000 description 4
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 4
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 4
- NBKLEMWHDLAUEM-CIUDSAMLSA-N Asp-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N NBKLEMWHDLAUEM-CIUDSAMLSA-N 0.000 description 4
- NWAHPBGBDIFUFD-KKUMJFAQSA-N Asp-Tyr-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O NWAHPBGBDIFUFD-KKUMJFAQSA-N 0.000 description 4
- MFDPBZAFCRKYEY-LAEOZQHASA-N Asp-Val-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MFDPBZAFCRKYEY-LAEOZQHASA-N 0.000 description 4
- GXIUDSXIUSTSLO-QXEWZRGKSA-N Asp-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CC(=O)O)N GXIUDSXIUSTSLO-QXEWZRGKSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- AMHIFFIUJOJEKJ-SZMVWBNQSA-N Gln-Lys-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N AMHIFFIUJOJEKJ-SZMVWBNQSA-N 0.000 description 4
- MLILEEIVMRUYBX-NHCYSSNCSA-N Glu-Val-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MLILEEIVMRUYBX-NHCYSSNCSA-N 0.000 description 4
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 description 4
- HDODQNPMSHDXJT-GHCJXIJMSA-N Ile-Asn-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O HDODQNPMSHDXJT-GHCJXIJMSA-N 0.000 description 4
- 108010025815 Kanamycin Kinase Proteins 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- BABSVXFGKFLIGW-UWVGGRQHSA-N Leu-Gly-Arg Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCNC(N)=N BABSVXFGKFLIGW-UWVGGRQHSA-N 0.000 description 4
- FLNPJLDPGMLWAU-UWVGGRQHSA-N Leu-Met-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(C)C FLNPJLDPGMLWAU-UWVGGRQHSA-N 0.000 description 4
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 4
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 4
- IMNVAOPEMFDAQD-NHCYSSNCSA-N Pro-Val-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IMNVAOPEMFDAQD-NHCYSSNCSA-N 0.000 description 4
- BRKHVZNDAOMAHX-BIIVOSGPSA-N Ser-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N BRKHVZNDAOMAHX-BIIVOSGPSA-N 0.000 description 4
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 4
- UFKPDBLKLOBMRH-XHNCKOQMSA-N Ser-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)C(=O)O UFKPDBLKLOBMRH-XHNCKOQMSA-N 0.000 description 4
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 4
- ABCLYRRGTZNIFU-BWAGICSOSA-N Thr-Tyr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N)O ABCLYRRGTZNIFU-BWAGICSOSA-N 0.000 description 4
- DJIJBQYBDKGDIS-JYJNAYRXSA-N Tyr-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(C)C)C(O)=O DJIJBQYBDKGDIS-JYJNAYRXSA-N 0.000 description 4
- YFOCMOVJBQDBCE-NRPADANISA-N Val-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N YFOCMOVJBQDBCE-NRPADANISA-N 0.000 description 4
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 4
- JXWGBRRVTRAZQA-ULQDDVLXSA-N Val-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N JXWGBRRVTRAZQA-ULQDDVLXSA-N 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108010059459 arginyl-threonyl-phenylalanine Proteins 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 108010015792 glycyllysine Proteins 0.000 description 4
- 108010083708 leucyl-aspartyl-valine Proteins 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000001323 posttranslational effect Effects 0.000 description 4
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 239000012723 sample buffer Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010020532 tyrosyl-proline Proteins 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- WQVYAWIMAWTGMW-ZLUOBGJFSA-N Ala-Asp-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N WQVYAWIMAWTGMW-ZLUOBGJFSA-N 0.000 description 3
- PGNNQOJOEGFAOR-KWQFWETISA-N Ala-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 PGNNQOJOEGFAOR-KWQFWETISA-N 0.000 description 3
- 101710194180 Alcohol oxidase 1 Proteins 0.000 description 3
- YUIGJDNAGKJLDO-JYJNAYRXSA-N Arg-Arg-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YUIGJDNAGKJLDO-JYJNAYRXSA-N 0.000 description 3
- FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 3
- IDDMGSKZQDEDGA-SRVKXCTJSA-N Asp-Phe-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 IDDMGSKZQDEDGA-SRVKXCTJSA-N 0.000 description 3
- ZQFRDAZBTSFGGW-SRVKXCTJSA-N Asp-Ser-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ZQFRDAZBTSFGGW-SRVKXCTJSA-N 0.000 description 3
- 108091033380 Coding strand Proteins 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- ZEXHDOQQYZKOIB-ACZMJKKPSA-N Cys-Glu-Ser Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZEXHDOQQYZKOIB-ACZMJKKPSA-N 0.000 description 3
- BSFFNUBDVYTDMV-WHFBIAKZSA-N Cys-Gly-Asn Chemical compound [H]N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BSFFNUBDVYTDMV-WHFBIAKZSA-N 0.000 description 3
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 3
- JILRMFFFCHUUTJ-ACZMJKKPSA-N Gln-Ser-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O JILRMFFFCHUUTJ-ACZMJKKPSA-N 0.000 description 3
- ZQYZDDXTNQXUJH-CIUDSAMLSA-N Glu-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)N ZQYZDDXTNQXUJH-CIUDSAMLSA-N 0.000 description 3
- IRJWAYCXIYUHQE-WHFBIAKZSA-N Gly-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)CN IRJWAYCXIYUHQE-WHFBIAKZSA-N 0.000 description 3
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 3
- CLVUXCBGKUECIT-HJGDQZAQSA-N Leu-Asp-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CLVUXCBGKUECIT-HJGDQZAQSA-N 0.000 description 3
- JNDYEOUZBLOVOF-AVGNSLFASA-N Leu-Leu-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O JNDYEOUZBLOVOF-AVGNSLFASA-N 0.000 description 3
- KZZCOWMDDXDKSS-CIUDSAMLSA-N Leu-Ser-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O KZZCOWMDDXDKSS-CIUDSAMLSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- OOLOTUZJUBOMAX-GUBZILKMSA-N Pro-Ala-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OOLOTUZJUBOMAX-GUBZILKMSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- YUSRGTQIPCJNHQ-CIUDSAMLSA-N Ser-Arg-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O YUSRGTQIPCJNHQ-CIUDSAMLSA-N 0.000 description 3
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 3
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 3
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 3
- HAYADTTXNZFUDM-IHRRRGAJSA-N Ser-Tyr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O HAYADTTXNZFUDM-IHRRRGAJSA-N 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 241000203644 Streptoalloteichus hindustanus Species 0.000 description 3
- FJKXUIJOMUWCDD-FHWLQOOXSA-N Tyr-Gln-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N)O FJKXUIJOMUWCDD-FHWLQOOXSA-N 0.000 description 3
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 3
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 3
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 3
- JSOXWWFKRJKTMT-WOPDTQHZSA-N Val-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N JSOXWWFKRJKTMT-WOPDTQHZSA-N 0.000 description 3
- 108010084758 arginyl-tyrosyl-aspartic acid Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 108010050848 glycylleucine Proteins 0.000 description 3
- 108010018006 histidylserine Proteins 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 108010078274 isoleucylvaline Proteins 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 2
- CJQAEJMHBAOQHA-DLOVCJGASA-N Ala-Phe-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N CJQAEJMHBAOQHA-DLOVCJGASA-N 0.000 description 2
- GMGWOTQMUKYZIE-UBHSHLNASA-N Ala-Pro-Phe Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 GMGWOTQMUKYZIE-UBHSHLNASA-N 0.000 description 2
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 2
- YCTIYBUTCKNOTI-UWJYBYFXSA-N Ala-Tyr-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCTIYBUTCKNOTI-UWJYBYFXSA-N 0.000 description 2
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 2
- IARGXWMWRFOQPG-GCJQMDKQSA-N Asn-Ala-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IARGXWMWRFOQPG-GCJQMDKQSA-N 0.000 description 2
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 2
- YRZIYQGXTSBRLT-AVGNSLFASA-N Asp-Phe-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O YRZIYQGXTSBRLT-AVGNSLFASA-N 0.000 description 2
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 2
- RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 108050001049 Extracellular proteins Proteins 0.000 description 2
- CVRUVYDNRPSKBM-QEJZJMRPSA-N Gln-Trp-Ser Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)N)N CVRUVYDNRPSKBM-QEJZJMRPSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- QTUSJASXLGLJSR-OSUNSFLBSA-N Ile-Arg-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N QTUSJASXLGLJSR-OSUNSFLBSA-N 0.000 description 2
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 2
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 2
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 2
- STAVRDQLZOTNKJ-RHYQMDGZSA-N Leu-Arg-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O STAVRDQLZOTNKJ-RHYQMDGZSA-N 0.000 description 2
- HYIFFZAQXPUEAU-QWRGUYRKSA-N Leu-Gly-Leu Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C HYIFFZAQXPUEAU-QWRGUYRKSA-N 0.000 description 2
- AUBMZAMQCOYSIC-MNXVOIDGSA-N Leu-Ile-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O AUBMZAMQCOYSIC-MNXVOIDGSA-N 0.000 description 2
- OMHLATXVNQSALM-FQUUOJAGSA-N Leu-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(C)C)N OMHLATXVNQSALM-FQUUOJAGSA-N 0.000 description 2
- FKQPWMZLIIATBA-AJNGGQMLSA-N Leu-Lys-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FKQPWMZLIIATBA-AJNGGQMLSA-N 0.000 description 2
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 2
- DRCILAJNUJKAHC-SRVKXCTJSA-N Lys-Glu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DRCILAJNUJKAHC-SRVKXCTJSA-N 0.000 description 2
- DSWOTZCVCBEPOU-IUCAKERBSA-N Met-Arg-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CCCNC(N)=N DSWOTZCVCBEPOU-IUCAKERBSA-N 0.000 description 2
- MYAPQOBHGWJZOM-UWVGGRQHSA-N Met-Gly-Leu Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(C)C MYAPQOBHGWJZOM-UWVGGRQHSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- DFEVBOYEUQJGER-JURCDPSOSA-N Phe-Ala-Ile Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O DFEVBOYEUQJGER-JURCDPSOSA-N 0.000 description 2
- RLUMIJXNHJVUCO-JBACZVJFSA-N Phe-Gln-Trp Chemical compound C([C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)C1=CC=CC=C1 RLUMIJXNHJVUCO-JBACZVJFSA-N 0.000 description 2
- ZLGQEBCCANLYRA-RYUDHWBXSA-N Phe-Gly-Glu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O ZLGQEBCCANLYRA-RYUDHWBXSA-N 0.000 description 2
- MTHRMUXESFIAMS-DCAQKATOSA-N Pro-Asn-Lys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O MTHRMUXESFIAMS-DCAQKATOSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- YIUWWXVTYLANCJ-NAKRPEOUSA-N Ser-Ile-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O YIUWWXVTYLANCJ-NAKRPEOUSA-N 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 2
- VASYSJHSMSBTDU-LKXGYXEUSA-N Thr-Asn-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CS)C(=O)O)N)O VASYSJHSMSBTDU-LKXGYXEUSA-N 0.000 description 2
- DCRHJDRLCFMEBI-RHYQMDGZSA-N Thr-Lys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O DCRHJDRLCFMEBI-RHYQMDGZSA-N 0.000 description 2
- FJBCEFPCVPHPPM-STECZYCISA-N Tyr-Ile-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O FJBCEFPCVPHPPM-STECZYCISA-N 0.000 description 2
- PFNZJEPSCBAVGX-CYDGBPFRSA-N Val-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N PFNZJEPSCBAVGX-CYDGBPFRSA-N 0.000 description 2
- NZYNRRGJJVSSTJ-GUBZILKMSA-N Val-Ser-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NZYNRRGJJVSSTJ-GUBZILKMSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 102000006646 aminoglycoside phosphotransferase Human genes 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 210000002288 golgi apparatus Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 235000019419 proteases Nutrition 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 108010080629 tryptophan-leucine Proteins 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 239000007222 ypd medium Substances 0.000 description 2
- YREOLPGEVLLKMB-UHFFFAOYSA-N 3-methylpyridin-1-ium-2-amine bromide hydrate Chemical compound O.[Br-].Cc1ccc[nH+]c1N YREOLPGEVLLKMB-UHFFFAOYSA-N 0.000 description 1
- WRDABNWSWOHGMS-UHFFFAOYSA-N AEBSF hydrochloride Chemical compound Cl.NCCC1=CC=C(S(F)(=O)=O)C=C1 WRDABNWSWOHGMS-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 1
- FVSOUJZKYWEFOB-KBIXCLLPSA-N Ala-Gln-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N FVSOUJZKYWEFOB-KBIXCLLPSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- DYXOFPBJBAHWFY-JBDRJPRFSA-N Ala-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N DYXOFPBJBAHWFY-JBDRJPRFSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 108020004217 Aminoglycoside phosphotransferase Proteins 0.000 description 1
- HPSVTWMFWCHKFN-GARJFASQSA-N Arg-Glu-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O HPSVTWMFWCHKFN-GARJFASQSA-N 0.000 description 1
- LVMUGODRNHFGRA-AVGNSLFASA-N Arg-Leu-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O LVMUGODRNHFGRA-AVGNSLFASA-N 0.000 description 1
- HNJNAMGZQZPSRE-GUBZILKMSA-N Arg-Pro-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O HNJNAMGZQZPSRE-GUBZILKMSA-N 0.000 description 1
- MOGMYRUNTKYZFB-UNQGMJICSA-N Arg-Thr-Phe Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MOGMYRUNTKYZFB-UNQGMJICSA-N 0.000 description 1
- INOIAEUXVVNJKA-XGEHTFHBSA-N Arg-Thr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O INOIAEUXVVNJKA-XGEHTFHBSA-N 0.000 description 1
- CGWVCWFQGXOUSJ-ULQDDVLXSA-N Arg-Tyr-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O CGWVCWFQGXOUSJ-ULQDDVLXSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RZVVKNIACROXRM-ZLUOBGJFSA-N Asn-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N RZVVKNIACROXRM-ZLUOBGJFSA-N 0.000 description 1
- XXAOXVBAWLMTDR-ZLUOBGJFSA-N Asn-Cys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N XXAOXVBAWLMTDR-ZLUOBGJFSA-N 0.000 description 1
- OLISTMZJGQUOGS-GMOBBJLQSA-N Asn-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N OLISTMZJGQUOGS-GMOBBJLQSA-N 0.000 description 1
- NLDNNZKUSLAYFW-NHCYSSNCSA-N Asn-Lys-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NLDNNZKUSLAYFW-NHCYSSNCSA-N 0.000 description 1
- HMQDRBKQMLRCCG-GMOBBJLQSA-N Asp-Arg-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HMQDRBKQMLRCCG-GMOBBJLQSA-N 0.000 description 1
- XDGBFDYXZCMYEX-NUMRIWBASA-N Asp-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)N)O XDGBFDYXZCMYEX-NUMRIWBASA-N 0.000 description 1
- BIVYLQMZPHDUIH-WHFBIAKZSA-N Asp-Gly-Cys Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)C(=O)O BIVYLQMZPHDUIH-WHFBIAKZSA-N 0.000 description 1
- JDDYEZGPYBBPBN-JRQIVUDYSA-N Asp-Thr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O JDDYEZGPYBBPBN-JRQIVUDYSA-N 0.000 description 1
- XWKBWZXGNXTDKY-ZKWXMUAHSA-N Asp-Val-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC(O)=O XWKBWZXGNXTDKY-ZKWXMUAHSA-N 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- KKZHXOOZHFABQQ-UWJYBYFXSA-N Cys-Ala-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKZHXOOZHFABQQ-UWJYBYFXSA-N 0.000 description 1
- IXPSSIBVVKSOIE-SRVKXCTJSA-N Cys-Ser-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)N)O IXPSSIBVVKSOIE-SRVKXCTJSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102100030012 Deoxyribonuclease-1 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical group [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- YJIUYQKQBBQYHZ-ACZMJKKPSA-N Gln-Ala-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O YJIUYQKQBBQYHZ-ACZMJKKPSA-N 0.000 description 1
- IIMZHVKZBGSEKZ-SZMVWBNQSA-N Gln-Trp-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O IIMZHVKZBGSEKZ-SZMVWBNQSA-N 0.000 description 1
- OACQOWPRWGNKTP-AVGNSLFASA-N Gln-Tyr-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O OACQOWPRWGNKTP-AVGNSLFASA-N 0.000 description 1
- GCYFUZJHAXJKKE-KKUMJFAQSA-N Glu-Arg-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GCYFUZJHAXJKKE-KKUMJFAQSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- GTFYQOVVVJASOA-ACZMJKKPSA-N Glu-Ser-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N GTFYQOVVVJASOA-ACZMJKKPSA-N 0.000 description 1
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 1
- AIJAPFVDBFYNKN-WHFBIAKZSA-N Gly-Asn-Asp Chemical compound C([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN)C(=O)N AIJAPFVDBFYNKN-WHFBIAKZSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- NKVZTQVGUNLLQW-JBDRJPRFSA-N Ile-Ala-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)O)N NKVZTQVGUNLLQW-JBDRJPRFSA-N 0.000 description 1
- WECYRWOMWSCWNX-XUXIUFHCSA-N Ile-Arg-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O WECYRWOMWSCWNX-XUXIUFHCSA-N 0.000 description 1
- OWSWUWDMSNXTNE-GMOBBJLQSA-N Ile-Pro-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N OWSWUWDMSNXTNE-GMOBBJLQSA-N 0.000 description 1
- YHFPHRUWZMEOIX-CYDGBPFRSA-N Ile-Val-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)O)N YHFPHRUWZMEOIX-CYDGBPFRSA-N 0.000 description 1
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 1
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- DUTMKEAPLLUGNO-JYJNAYRXSA-N Lys-Glu-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O DUTMKEAPLLUGNO-JYJNAYRXSA-N 0.000 description 1
- SLQJJFAVWSZLBL-BJDJZHNGSA-N Lys-Ile-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN SLQJJFAVWSZLBL-BJDJZHNGSA-N 0.000 description 1
- JYVCOTWSRGFABJ-DCAQKATOSA-N Lys-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCCN)N JYVCOTWSRGFABJ-DCAQKATOSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- QEVRUYFHWJJUHZ-DCAQKATOSA-N Met-Ala-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C QEVRUYFHWJJUHZ-DCAQKATOSA-N 0.000 description 1
- OBVHKUFUDCPZDW-JYJNAYRXSA-N Met-Arg-Phe Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OBVHKUFUDCPZDW-JYJNAYRXSA-N 0.000 description 1
- PCTFVQATEGYHJU-FXQIFTODSA-N Met-Ser-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O PCTFVQATEGYHJU-FXQIFTODSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- BRDYYVQTEJVRQT-HRCADAONSA-N Phe-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O BRDYYVQTEJVRQT-HRCADAONSA-N 0.000 description 1
- KIEPQOIQHFKQLK-PCBIJLKTSA-N Phe-Asn-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KIEPQOIQHFKQLK-PCBIJLKTSA-N 0.000 description 1
- VLZGUAUYZGQKPM-DRZSPHRISA-N Phe-Gln-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VLZGUAUYZGQKPM-DRZSPHRISA-N 0.000 description 1
- WKTSCAXSYITIJJ-PCBIJLKTSA-N Phe-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O WKTSCAXSYITIJJ-PCBIJLKTSA-N 0.000 description 1
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 1
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 1
- GMWNQSGWWGKTSF-LFSVMHDDSA-N Phe-Thr-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O GMWNQSGWWGKTSF-LFSVMHDDSA-N 0.000 description 1
- IWNOFCGBMSFTBC-CIUDSAMLSA-N Pro-Ala-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O IWNOFCGBMSFTBC-CIUDSAMLSA-N 0.000 description 1
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 1
- AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 description 1
- ITUDDXVFGFEKPD-NAKRPEOUSA-N Pro-Ser-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ITUDDXVFGFEKPD-NAKRPEOUSA-N 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 1
- ZXLUWXWISXIFIX-ACZMJKKPSA-N Ser-Asn-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZXLUWXWISXIFIX-ACZMJKKPSA-N 0.000 description 1
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 1
- DGPGKMKUNGKHPK-QEJZJMRPSA-N Ser-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CO)N DGPGKMKUNGKHPK-QEJZJMRPSA-N 0.000 description 1
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 1
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 1
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 1
- JCLAFVNDBJMLBC-JBDRJPRFSA-N Ser-Ser-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JCLAFVNDBJMLBC-JBDRJPRFSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- DYEGLQRVMBWQLD-IXOXFDKPSA-N Ser-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CO)N)O DYEGLQRVMBWQLD-IXOXFDKPSA-N 0.000 description 1
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 1
- HKHCTNFKZXAMIF-KKUMJFAQSA-N Ser-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CC=C(O)C=C1 HKHCTNFKZXAMIF-KKUMJFAQSA-N 0.000 description 1
- YEDSOSIKVUMIJE-DCAQKATOSA-N Ser-Val-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O YEDSOSIKVUMIJE-DCAQKATOSA-N 0.000 description 1
- 101150094640 Siae gene Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CAJFZCICSVBOJK-SHGPDSBTSA-N Thr-Ala-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O CAJFZCICSVBOJK-SHGPDSBTSA-N 0.000 description 1
- VIBXMCZWVUOZLA-OLHMAJIHSA-N Thr-Asn-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O VIBXMCZWVUOZLA-OLHMAJIHSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- PZSDPRBZINDEJV-HTUGSXCWSA-N Thr-Phe-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PZSDPRBZINDEJV-HTUGSXCWSA-N 0.000 description 1
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- VBMOVTMNHWPZJR-SUSMZKCASA-N Thr-Thr-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VBMOVTMNHWPZJR-SUSMZKCASA-N 0.000 description 1
- NHQVWACSJZJCGJ-FLBSBUHZSA-N Thr-Thr-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NHQVWACSJZJCGJ-FLBSBUHZSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- WKCFCVBOFKEVKY-HSCHXYMDSA-N Trp-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N WKCFCVBOFKEVKY-HSCHXYMDSA-N 0.000 description 1
- ARKBYVBCEOWRNR-UBHSHLNASA-N Trp-Ser-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O ARKBYVBCEOWRNR-UBHSHLNASA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- BARBHMSSVWPKPZ-IHRRRGAJSA-N Tyr-Asp-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BARBHMSSVWPKPZ-IHRRRGAJSA-N 0.000 description 1
- KCPFDGNYAMKZQP-KBPBESRZSA-N Tyr-Gly-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O KCPFDGNYAMKZQP-KBPBESRZSA-N 0.000 description 1
- WDGDKHLSDIOXQC-ACRUOGEOSA-N Tyr-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 WDGDKHLSDIOXQC-ACRUOGEOSA-N 0.000 description 1
- JLKVWTICWVWGSK-JYJNAYRXSA-N Tyr-Lys-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JLKVWTICWVWGSK-JYJNAYRXSA-N 0.000 description 1
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 1
- PVPAOIGJYHVWBT-KKHAAJSZSA-N Val-Asn-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N)O PVPAOIGJYHVWBT-KKHAAJSZSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- SJRUJQFQVLMZFW-WPRPVWTQSA-N Val-Pro-Gly Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SJRUJQFQVLMZFW-WPRPVWTQSA-N 0.000 description 1
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 1
- OFTXTCGQJXTNQS-XGEHTFHBSA-N Val-Thr-Ser Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](C(C)C)N)O OFTXTCGQJXTNQS-XGEHTFHBSA-N 0.000 description 1
- AOILQMZPNLUXCM-AVGNSLFASA-N Val-Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN AOILQMZPNLUXCM-AVGNSLFASA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000010310 bacterial transformation Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010079547 glutamylmethionine Proteins 0.000 description 1
- 230000001279 glycosylating effect Effects 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010087823 glycyltyrosine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010056929 lyticase Proteins 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000012092 media component Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A method is provided for the production of a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein. Methylotroghic yeast is used as a heterologous host organism. The bovine pancreatic protein is secreted into the growth medium from which it is purified.
Description
Recombinant bovine pancreatic desoxyribonuclease I with high specific activity Background of the invention The present invention relates - to the production of recombinant bovine pancreatic desoxyribonuclease I in methylotrophic yeast. In particular, the present invention relates to a bovine pancreatic desoxyribonuclease I that is secreted by the methylotrophic yeast into the growth medium from which it is purified. Also provided are use and kits of the recombinant bovine pancreatic desoxyribonuclease I.
Bovine pancreatic desoxyribonuclease I is an industrial product with a wide range of applications. For instance, applications in the field of cell biology make use of bovine pancreatic desoxyribonuclease I in standard laboratory procedures for the purpose of dissociating cell tissue and isolating single cells. Such processes are always accompanied by rupture and lysis of some cells. As a consequence, DNA is released from these cells into the intercellular space and/or the dissociation medium and causes unwanted cell clumping.
Adding bovine pancreatic desoxyribonuclease I to the dissociation medium is a preferred means to prevent unwanted cell clumping as the enzyme has been shown not to be cytotoxic in concentrations of up to 1 mg/ml. Thus, cell clumping is prevented by hydrolysing DNA. For purposes of tissue culture, bovine pancreatic desoxyribonuclease I is also used in combination with other enzymes such as collagenase or trypsin (Kaighn, M.E., In: Tissue culture, methods and applications; Kruse, P. F. & Patterson, M. K., eds., Academic Press, New York & London,1973, 54-58).
Regarding the fields of molecular biology and nucleic acid biochemistry, bovine pancreatic desoxyribonuclease I is used in applications such as nick translation, the production of random DNA fragments, desoxyribonuclease I protection assays such as transcription factor footprinting, removal of DNA template after in vitro transcription, removal of DNA
from RNA samples prior to applications such as RT-PCR, and removal of DNA from other preparations generated by biological and/or biochemical procedures, to name but a few (Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001). Thus, removal of DNA is effected by hydrolysing DNA.
DNase I is also used in medical applications aimed at reducing the viscoelasticity of pulmonary secretions (Liao, T.H., J. Formos. Med. Assoc. 96 (1997) 481-487).
Whereas for this particular purpose desoxyribonuclease I of human origin is the preferred enzyme, desoxyribonuclease I from bovine pancreas is preferred for the different kinds of research r use exemplified above. Thus, bovine pancreatic desoxyribonuclease I is an enzyme that is produced in an industrial scale and sold as a regular industrial product (e.g.
desoxyribonuclease I from bovine pancreas EC 3.1.21.1, Item No. 1284932 in the catalogue of Roche Diagnostics GmbH, Mannheim).
Bovine pancreatic desoxyribonuclease I has a molecular weight of about 30,000 daltons and an enzymatic activity optimum at pH. 7.8. Bovine pancreatic desoxyribonuclease I
hydrolyses phosphodiester linkages of DNA, preferentially adjacent to a pyrimidine nucleotide yielding DNA molecules with a free hydroxyl group at the 3' position and a phosphate group at the 5' position. The average chain length of a limit digest is a tetranucleotide. There are four desoxyribonucleases derived from bovine pancreas which are all glycoproteins. They differ from each other either in a carbohydrate side chain or polypeptide component. Bovine pancreatic desoxyribonuclease I has diverse chemical activity acting upon single stranded DNA, double stranded DNA and chromatin (Liao, T.H., Mol. Cell Biochem. 34 (1981) 15-22). Similarly to other desoxyribonucleases, bovine pancreatic desoxyribonuclease I appears to be modulated in vivo by actin which is taking the effect as a cellular inhibitor (Lazarides, E., and Lindberg, U., Proc.
Natl. Acad. Sci. USA
71 (1974) 4742). Moreover, like other desoxyribonucleases, bovine pancreatic desoxyribonuclease I is activated by divalent metal ions. Maximum activation is attained with Mg 2+ and Ca2+. A metallosubstrate, such as a magnesium salt of DNA is necessary.
Citrate completely inhibits magnesium-activated but not manganese-activated desoxyribonuclease I. Desoxyribonuclease I is inhibited by chelating agents such as EDTA, and by sodium dodecyl sulfate (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001).
When desoxyribonuclease activity is quantified, the present document refers to "units Thus, the nucleolytic activity of bovine pancreatic desoxyribonuclease I is quantified using a photometric assay similar to Kunitz, M. (J. Gen. Physiol. 33 (1950) 349-62 and 363). The "specific desoxyribonuclease activity" or "specific activity" of a given preparation is defined as the number of units per mg of protein in the preparation, determined by the method described in detail in Example 11.
A "methylotrophic yeast" is defined as a yeast that is capable of utilising methanol as its carbon source. The term also comprises laboratory strains thereof. In case a methylotrophic yeast strain is auxotrophic and because of this needs to be supplemented, with an auxillary carbon-containing substance such as, e.g. histidine in the case of a methylotrophic yeast strain unable to synthesise this amino acid in sufficient amounts, this auxiliary substance is regarded as a nutrient but not as a carbon source.
A "vector" is defined as DNA which can comprise, i.e. carry and maintain the DNA
fragment of the invention, including, for example, phages and plasmids. These terms are understood by those of skill in the art of genetic engineering. The term "expression cassette" denotes a nucleotide sequence encoding a pre-protein, operably linked to a promoter and a terminator. As for vectors containing an expression cassette, the terms "vector" and "expression vector" are synonyms.
The term "oligonucleotide" is used for a nucleic acid molecule, DNA (or RNA), with less than 100 nucleotides in length.
"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration.
The term "expression" and the verb "to express" denote transcription of DNA
sequences and/or the translation of the transcribed mRNA in a host organism resulting in a pre-protein, i.e. not including post-translational processes.
A nucleotide sequence "encodes" a peptide or protein when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the peptide or protein, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the peptide or protein in vitro, in a prokaryotic host cell, or in a eukaryotic host cell.
A "promoter" is a regulatory nucleotide sequence that stimulates transcription. These terms are understood by those of skill in the art of genetic engineering. Like a promoter, a "promoter element" stimulates transcription but constitutes a sub-fragment of a larger promoter sequence.
The term "operably linked" refers to the association of two or more nucleic acid fragments on a single vector so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence, i.e. a nucleotide sequence encoding a protein or a pre-protein, when it is capable of affecting the expression of that coding sequence, i.e., that the coding sequence is under the transcriptional control of the promoter.
Bovine pancreatic desoxyribonuclease I is an industrial product with a wide range of applications. For instance, applications in the field of cell biology make use of bovine pancreatic desoxyribonuclease I in standard laboratory procedures for the purpose of dissociating cell tissue and isolating single cells. Such processes are always accompanied by rupture and lysis of some cells. As a consequence, DNA is released from these cells into the intercellular space and/or the dissociation medium and causes unwanted cell clumping.
Adding bovine pancreatic desoxyribonuclease I to the dissociation medium is a preferred means to prevent unwanted cell clumping as the enzyme has been shown not to be cytotoxic in concentrations of up to 1 mg/ml. Thus, cell clumping is prevented by hydrolysing DNA. For purposes of tissue culture, bovine pancreatic desoxyribonuclease I is also used in combination with other enzymes such as collagenase or trypsin (Kaighn, M.E., In: Tissue culture, methods and applications; Kruse, P. F. & Patterson, M. K., eds., Academic Press, New York & London,1973, 54-58).
Regarding the fields of molecular biology and nucleic acid biochemistry, bovine pancreatic desoxyribonuclease I is used in applications such as nick translation, the production of random DNA fragments, desoxyribonuclease I protection assays such as transcription factor footprinting, removal of DNA template after in vitro transcription, removal of DNA
from RNA samples prior to applications such as RT-PCR, and removal of DNA from other preparations generated by biological and/or biochemical procedures, to name but a few (Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001). Thus, removal of DNA is effected by hydrolysing DNA.
DNase I is also used in medical applications aimed at reducing the viscoelasticity of pulmonary secretions (Liao, T.H., J. Formos. Med. Assoc. 96 (1997) 481-487).
Whereas for this particular purpose desoxyribonuclease I of human origin is the preferred enzyme, desoxyribonuclease I from bovine pancreas is preferred for the different kinds of research r use exemplified above. Thus, bovine pancreatic desoxyribonuclease I is an enzyme that is produced in an industrial scale and sold as a regular industrial product (e.g.
desoxyribonuclease I from bovine pancreas EC 3.1.21.1, Item No. 1284932 in the catalogue of Roche Diagnostics GmbH, Mannheim).
Bovine pancreatic desoxyribonuclease I has a molecular weight of about 30,000 daltons and an enzymatic activity optimum at pH. 7.8. Bovine pancreatic desoxyribonuclease I
hydrolyses phosphodiester linkages of DNA, preferentially adjacent to a pyrimidine nucleotide yielding DNA molecules with a free hydroxyl group at the 3' position and a phosphate group at the 5' position. The average chain length of a limit digest is a tetranucleotide. There are four desoxyribonucleases derived from bovine pancreas which are all glycoproteins. They differ from each other either in a carbohydrate side chain or polypeptide component. Bovine pancreatic desoxyribonuclease I has diverse chemical activity acting upon single stranded DNA, double stranded DNA and chromatin (Liao, T.H., Mol. Cell Biochem. 34 (1981) 15-22). Similarly to other desoxyribonucleases, bovine pancreatic desoxyribonuclease I appears to be modulated in vivo by actin which is taking the effect as a cellular inhibitor (Lazarides, E., and Lindberg, U., Proc.
Natl. Acad. Sci. USA
71 (1974) 4742). Moreover, like other desoxyribonucleases, bovine pancreatic desoxyribonuclease I is activated by divalent metal ions. Maximum activation is attained with Mg 2+ and Ca2+. A metallosubstrate, such as a magnesium salt of DNA is necessary.
Citrate completely inhibits magnesium-activated but not manganese-activated desoxyribonuclease I. Desoxyribonuclease I is inhibited by chelating agents such as EDTA, and by sodium dodecyl sulfate (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001).
When desoxyribonuclease activity is quantified, the present document refers to "units Thus, the nucleolytic activity of bovine pancreatic desoxyribonuclease I is quantified using a photometric assay similar to Kunitz, M. (J. Gen. Physiol. 33 (1950) 349-62 and 363). The "specific desoxyribonuclease activity" or "specific activity" of a given preparation is defined as the number of units per mg of protein in the preparation, determined by the method described in detail in Example 11.
A "methylotrophic yeast" is defined as a yeast that is capable of utilising methanol as its carbon source. The term also comprises laboratory strains thereof. In case a methylotrophic yeast strain is auxotrophic and because of this needs to be supplemented, with an auxillary carbon-containing substance such as, e.g. histidine in the case of a methylotrophic yeast strain unable to synthesise this amino acid in sufficient amounts, this auxiliary substance is regarded as a nutrient but not as a carbon source.
A "vector" is defined as DNA which can comprise, i.e. carry and maintain the DNA
fragment of the invention, including, for example, phages and plasmids. These terms are understood by those of skill in the art of genetic engineering. The term "expression cassette" denotes a nucleotide sequence encoding a pre-protein, operably linked to a promoter and a terminator. As for vectors containing an expression cassette, the terms "vector" and "expression vector" are synonyms.
The term "oligonucleotide" is used for a nucleic acid molecule, DNA (or RNA), with less than 100 nucleotides in length.
"Transformation" means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration.
The term "expression" and the verb "to express" denote transcription of DNA
sequences and/or the translation of the transcribed mRNA in a host organism resulting in a pre-protein, i.e. not including post-translational processes.
A nucleotide sequence "encodes" a peptide or protein when at least a portion of the nucleic acid, or its complement, can be directly translated to provide the amino acid sequence of the peptide or protein, or when the isolated nucleic acid can be used, alone or as part of an expression vector, to express the peptide or protein in vitro, in a prokaryotic host cell, or in a eukaryotic host cell.
A "promoter" is a regulatory nucleotide sequence that stimulates transcription. These terms are understood by those of skill in the art of genetic engineering. Like a promoter, a "promoter element" stimulates transcription but constitutes a sub-fragment of a larger promoter sequence.
The term "operably linked" refers to the association of two or more nucleic acid fragments on a single vector so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence, i.e. a nucleotide sequence encoding a protein or a pre-protein, when it is capable of affecting the expression of that coding sequence, i.e., that the coding sequence is under the transcriptional control of the promoter.
The term "polypeptide" or "protein" denotes a polymer composed of more than 90 amino acid monomers joined by peptide bonds. The term "peptide" denotes an oligomer composed of 90 or fewer amino acid.monomers joined by peptide bonds. A
"peptide bond"
is a covalent bond between two amino acids in which the a-amino group of one amino acid is bonded to the a-carboxyl group of the other amino acid.
The term "pre-protein" denotes a primary translation product that is a precursor of a mature protein, i.e. in this case a protein results from post-translational processing of a pre-protein.
The term "post-translational processing" denotes the modification steps a pre-protein is subjected to, in order result in a mature protein in a cellular or extracellular compartment.
A "signal peptide" is a cleavable signal sequence of amino acids present in the pre-protein form of a secretable protein. Proteins transported across the cell membrane, i.e. "secreted", typically have an N- terminal sequence rich in hydrophobic amino acids about 15 to 30 amino acids long. Sometime during the process of passing through the membrane, the signal sequence is cleaved by a signal peptidase (Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing). Many sources of signal peptides are well known to those skilled in the art and can include, for example, the amino acid sequence of the a-factor signal peptide from Saccharomyces cerevisiae and the like. Another example is the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. In general, the pre protein N-terminus of essentially any secreted protein is a potential source of a signal peptide suitable for use in the present invention. A signal peptide can also be bipartite comprising two signal peptides directing the pre-protein to a first and a second cellular compartment. Bipartite signal peptides are cleaved off stepwise during the course of the secretory pathway. A specific example therefor is the prepro peptide of the a-factor from Saccharomyces cerevisiae (Waters et al., J. Biol. Chem. 263 (1988) 6209-14).
Pre-proteins with an N-terminal signal peptide are directed to enter the "secretory pathway". The secretory pathway comprises the processes of post-translational processing and finally results in secretion of a protein. Glycosylation and the formation of disulfide bonds are processes that are part of the secretory pathway prior to secretion.
In the present document it is understood that proteins secreted by methylotrophic yeast strains have passed through the secretory pathway.
"peptide bond"
is a covalent bond between two amino acids in which the a-amino group of one amino acid is bonded to the a-carboxyl group of the other amino acid.
The term "pre-protein" denotes a primary translation product that is a precursor of a mature protein, i.e. in this case a protein results from post-translational processing of a pre-protein.
The term "post-translational processing" denotes the modification steps a pre-protein is subjected to, in order result in a mature protein in a cellular or extracellular compartment.
A "signal peptide" is a cleavable signal sequence of amino acids present in the pre-protein form of a secretable protein. Proteins transported across the cell membrane, i.e. "secreted", typically have an N- terminal sequence rich in hydrophobic amino acids about 15 to 30 amino acids long. Sometime during the process of passing through the membrane, the signal sequence is cleaved by a signal peptidase (Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing). Many sources of signal peptides are well known to those skilled in the art and can include, for example, the amino acid sequence of the a-factor signal peptide from Saccharomyces cerevisiae and the like. Another example is the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. In general, the pre protein N-terminus of essentially any secreted protein is a potential source of a signal peptide suitable for use in the present invention. A signal peptide can also be bipartite comprising two signal peptides directing the pre-protein to a first and a second cellular compartment. Bipartite signal peptides are cleaved off stepwise during the course of the secretory pathway. A specific example therefor is the prepro peptide of the a-factor from Saccharomyces cerevisiae (Waters et al., J. Biol. Chem. 263 (1988) 6209-14).
Pre-proteins with an N-terminal signal peptide are directed to enter the "secretory pathway". The secretory pathway comprises the processes of post-translational processing and finally results in secretion of a protein. Glycosylation and the formation of disulfide bonds are processes that are part of the secretory pathway prior to secretion.
In the present document it is understood that proteins secreted by methylotrophic yeast strains have passed through the secretory pathway.
Until presently, a major source of bovine pancreatic desoxyribonuclease I is pancreatic tissue obtained from slaughtered cattle. The enzyme is usually purified from the tissue' material using chromatographic separation techniques such as those described by Funakoshi, A., et al., J. Biochem. (Tokyo) 88 (1980) 1113-1138; Paudel, H.K., and Liao, T.H., J. Biol Chem. 261 (1986) 16006-16011; and Nefsky, B., and Bretscher, A., Eur. J.
Biochem. 179 (1989) 215-219. The purification process under the conditions of a research laboratory yields a specific activitiy in the range of 1,000 units per mg of protein obtained from 400 g of tissue, as explicitly reported by Paudel, H.K., and Liao, T.H., J. Biol Chem.
261 (1986) 16006-16011. In an upscaled industrial process, the isolation of bovine pancreatic desoxyribonuclease I from bovine pancreatic tissue yields preparations of isolated enzyme which usually exhibit a specific activity of 3,500 units per mg of protein (our own unpublished observation). Commercial preparations of research-grade bovine pancreatic desoxyribonuclease I purified from bovine pancreas usually have a specific activity below this value as exemplified by Roche products (Roche Diagnostics GmbH, Mannheim, Germany; catalogue items as of November 2002) having the catalogue numbers 1284932 (2,000 units/mg), 104132 (3,000 units/mg), 104159 (2,000 units/mg), and Sigma-Aldrich products (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany;
catalogue items as of November 2002) having the catalogue numbers D5025 (2,000 units/mg) D4263 (2,000 U/mg), D4513 (2,000 units/mg), DN-25 (400-800 units/mg).
Generally, pancreas tissue as source for bovine pancreatic desoxyribonuclease I poses a problem as this tissue has a high content of other digestive pro-enzymes and their activated forms. On the one hand, the mixture from which the desired enzyme is purified is therefore very complex and requires elaborate separation techniques. On the other hand, proteases among the digestive enzymes may destroy the desired protein, especially during the first steps of the purification process when pancreatic tissue is homogenised. One could also speculate that pancreatic tissue homogenate contains inhibitory substances that inactivate a substantial portion of the bovine pancreatic desoxyribonuclease I, thereby limiting the specific activity of active enzyme that can be purified from this source.
It is also known to the art that recombinant expression of an enzymatically active bovine pancreatic desoxyribonuclease I protein in a bacterial host is possible.
However, overexpression poses a problem owing to the intrinsic toxicity of an endonuclease for a bacterial cell. Apparently, toxicity is caused by intracellular degradation of host cell DNA
with high levels of active bovine pancreatic desoxyribonuclease I enzyme being present in the bacterial cytoplasm. In a bacterial cell transcription and translation are tightly connected as opposed to eukaryotic cells where these processes take place in separate compartments, i.e. the nucleus and the cytoplasm. Thus, the selection of bacterial clones overexpressing bovine pancreatic desoxyribonuclease I at the same time promotes instability of these clones (e.g. genetic instability) and/or the recombinant desoxyribonuclease protein to be produced. Attempts to overcome this problem were mainly based on tightly regulated and inducible bacterial expression systems.
Worrall, A.F., and Connolly, B.A. (J. Biol. Chem. 265 (1990) 21889-21895) expressed an active bovine pancreatic desoxyribonuclease I protein in E. coli making use of a synthetic coding sequence adapted to the codon usage of the host organism.
Transcriptional expression was under the control of the XpL promoter. The recombinant protein was produced intracellularly and afterwards solubilised by means of sonication.
The recombinant active protein was found to be toxic for the bacterial host stain.
Thus, expression yield was in the range between 100 g to 1 mg/i culture. The specific activity of the recombinant active bovine pancreatic desoxyribonuclease I from E. coli was found to be identical to that of the native protein. The value given in the document (5x108 units/g of protein) was not the true value of the preparation but was corrected for purity. The recombinant bovine pancreatic desoxyribonuclease I protein was purified only partially and the document is completely silent about the specific desoxyribonuclease activity of a substantially pure and/or research-grade product.
Chen, C.Y., et al. (Gene 206 (1998) 181-184) expressed in E. coli a cDNA
representing the original bovine pancreatic transcript.: The construct was expressed in the strain BL21(DE3)pLysE and transcribed by an IPTG-inducible T7 polymerase. However, overexpression of an active bovine pancreatic desoxyribonuclease I was found to be limited in quantity and the product appeared to be toxic for the bacterial host organism. Due to cell lysis upon induction, bovine pancreatic desoxyribonuclease I activity was found in, the supernatant but also in the cellular fraction of the culture.
desoxyribonuclease enzyme activity was measured using an assay for enzyme activity that differed from the Kunitz assay in that there are changes with respect to divalent cations and their.
concentration in the reaction buffer, as well as its pH. However, generally the units detected by this assay appear to be comparable to those of the Kunitz assay. According to the assay of this document, the approximate yield from the induced culture was 3,500 units/l. The specific enzyme activity of the recombinant bovine pancreatic desoxyribonuclease I produced in E. coli was 908 units/mg was in the same range as the specific activity of native bovine pancreatic desoxyribonuclease I purified in parallel from pancreatic tissue (938 units/mg).
As it is commonly observed when post-translationally processed proteins of eukaryotic origin are expressed in a prokaryotic host system, the bovine pancreatic desoxyribonuclease I obtained by means of recombinant expression in E. coli markedly differs from the native protein. Particularly N-glycosylation which is a hallmark of the native pancreatic desoxyribonuclease I protein is absent in the recombinant product derived from prokaryotic expression systems. Glycosylation does not take place in E. coli and the publications by Worrall, A.F., and Connolly, B.A., J. Biol. Chem. 265 (1990) 21889-21895 as well as Chen, C.Y., et al., Gene 206 _ (1998) 181-184, confirm that the recombinantly produced bovine pancreatic desoxyribonuclease I proteins were not glycosylated. Also, folding of the protein and the formation of disulfide bonds are controlled differently in eukaryotic cells (Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing). Above all, the formation of disulfide bridges in the recombinantly produced protein can be assumed to occur randomly once SH groups of the protein come in contact with aerial oxygen.
Glycosylated bovine pancreatic desoxyribonuclease I also was expressed in cultured mammalian cells. Nishikawa, A., et al. (J. Biol. Chem. 272 (1997) 19408-19412) produced bovine pancreatic desoxyribonuclease I as well as human desoxyribonuclease I
in COS-1 cells in order to study mannose phosphorylation of these proteins. The document is however completely silent regarding yield or activity of the recombinant desoxyribonuclease I produced. A further glycosylation study on bovine pancreatic desoxyribonuclease I was published by Nishikawa, A., and Mizuno, S., Biochem.
J. 355 (2001) 245-248, dealing with the efficiency of N-linked glycosylation of bovine pancreatic desoxyribonuclease I. Also this document is completely silent regarding yield or activity of the recombinant desoxyribonuclease I produced.
Recombinant expression of human pancreatic desoxyribonuclease I in embryonic kidney 293 cells was described by Shak, S., Proc. Natl. Acad. Sci. USA 87 (1990) 9188-9192 as well as by the same author in WO 90/07572. In the latter document it is stated that the specific activity of recombinant human pancreatic desoxyribonuclease from 293 cells appeared to be comparable to that of bovine desoxyribonuclease (Sigma, product D5025) which was used as a reference. According to the supplier's (Sigma) catalogue the product has a specific activity of 2,000 units/mg which puts the recombinantly expressed human pancreatic desoxyribonuclease I protein in the same range. Moreover, according to the invention described in WO 90/07572, recombinant desoxyribonuclease is preferably expressed in mammalian cells but also in prokaryotes, fungi, yeast, pichia, insects and the like. However, apart from expression in mammalian cells the document does not disclose any other example for eukaryotic expression systems. Moreover, the document is completely silent regarding glycosylation, the formation of disulfide bridges and the specific activity of recombinant desoxyribonuclease when produced in other eukaryotic expression systems.
Furthermore, the document is completely silent on the impact of secretion on the yield of the desired protein as well as on its activity.
Using a similar expression system as in WO 90/07572, WO 96/26278 describes the production of human desoxyribonuclease I variants that exhibit a reduced binding affinity to actin. EP 1 122 306 discloses the expression of a human desoxyribonuclease II in HeLa cells.
The methods that are provided by the state of the art to produce a bovine pancreatic protein with desoxyribonuclease activity have certain disadvantages. The present invention provides an improved method.
It is an object of the invention to provide a cost-effective alternative source for bovine pancreatic desoxyribonuclease I. It is a further object of the invention to purify bovine pancreatic desoxyribonuclease I as a recombinant protein synthesised by a non-animal host organism. It is another object of the invention to provide an expression system in which the host organism tolerates the recombinant bovine pancreatic desoxyribonuclease I
better than bacteria. Another object of the invention is to provide an expression system which simplifies and accelerates the separation of bovine pancreatic desoxyribonuclease I from cellular or media components, therefore conserving enzyme activity which otherwise may be lost. Yet another object of the invention is to provide a production procedure that leads to an enzyme preparation with a high specific activity. Yet another object of the invention is that the production procedure is amenable to upscaling towards a cost-effective industrial process.
Brief summary of the invention It was surprisingly found that in case bovine pancreatic desoxyribonuclease I
is recombinatly expressed in the form of a pre-protein in methylotrophic yeast, whereby the methylotrophic yeast secretes the mature protein, the purified protein has an exceptionally high specific activity, that is to say a specific activity equal or higher than 6,000 units per mg of protein.
Thus, according to the invention, there is provided a method to produce a bovine pancreatic protein with desoxyribonuclease activity, comprising the steps of (a) providing a _9_ vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and' whereby the bovine pancreatic protein purified in step (d) is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein.
Therefore, the product is defined as a bovine pancreatic protein, obtainable by the method comprising the steps of (a) providing a vector comprising. a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and whereby the bovine pancreatic protein is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein Detailed description of the invention The enzyme bovine pancreatic desoxyribonuclease I is produced using methylotrophic yeast as a non-animal host organism. Methylotrophic yeasts have the biochemical pathways necessary for methanol utilization and are classified into four genera, based upon cell morphology and growth characteristics: Hansenula, Pichia, Candida, and Torulopsis. The most highly developed methylotrophic host systems utilize Pichia pastoris (Komagataella pastoris) and Hansenula polymorpha (Pichia angusta).
Expression of heterologous proteins in yeast is described in US 5,618,676, US
5,854,018, US 5,856,123, and US 5,919,651.
Yeast organisms produce a number of proteins that are synthesized intracellularly but have a function outside the cell. These extracellular proteins are referred to as secreted proteins.
Initially, the secreted proteins are expressed inside the cell in the form of a precursor or a pre-protein containing an N-terminal signal peptide ensuring effective direction of the expressed product into the secretory pathway of the cell, across the membrane of the endoplasmic reticulum. The signal peptide is generally cleaved off from the desired product during translocation. Cleavage is effected proteolytically by a signal peptidase. A particular sub-sequence of amino acids of the signal peptide is recognised and leaved by the signal peptidase. This sub-sequence is referred to as signal peptidase cleavage site.
Once having entered the secretory pathway, the protein is transported to the Golgi apparatus. From the Golgi apparatus the proteins are distributed to the plasma membrane, lysosomes and secretory vesicles.
Secreted proteins are confronted with different environmental conditions as opposed to intracellular proteins. Part of the processes of the secretory pathway is to stabilise the maturing extracellular proteins. Therefore, pre-proteins that are passed through the secretory pathway of yeast undergo specific posttranslational processing. For example, processing can comprise the generation of disulfide bonds to form intramolecular cross-links. Moreover, certain amino acids of the protein can be glycosylated.
Several approaches have been suggested for the expression and secretion in yeast of proteins heterologous to yeast. EP 0 116 201 describes a process by which proteins heterologous to yeast are transformed by an expression vector harboring DNA
encoding the desired protein, a signal peptide and a peptide acting as a signal peptidase cleavage site.
A culture of the transformed organism is prepared and grown, and the protein is recovered from culture media. For use in yeast cells a suitable signal peptide has been found to be the a-factor signal peptide from Saccharomyces cerevisiae (US 4,870,008).
When the present invention was made it was found surprisingly that the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein is also sufficient to direct the pre-protein to the secretory pathway of methylotrophic yeast.
Therefore, the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein can be used to express and secrete a heterologous gene product in methylotrophic yeast.
During secretion, the yeast enzyme KEX-2 is the signal peptidase which recognizes a Lysine-Arginine sequence as its cleavage site in the pre-protein. KEX-2 cleaves at the junction to the. sequence of the desired protein. As a result, the desired gene product is released and free of the leader portions, i.e. the signal peptide of the pre-protein. KEX-2 endoprotease was originally characterised in Saccharomyces yeast where it specifically processes the precursor of mating type a-factor and a killer factor (Julius, D., et al., Cell 37 (1984) 1075-1089). Methylotrophic yeast species such as Pichia pastoris share the KEX-2-type protease (similar role and function) with Saccharomyces cerevisiae (Werten, M.W., et al., Yeast 15 (1999) 1087-1096).
A well-established methylotrophic yeast species exemplarily described as host for high-level recombinant protein expression is Pichia pastoris (US 4,683,293, US 4,808,537, US 4,812,405, US 4,818,700, US 4,837,148, US 4,855,231, US 4,857,467, US
4,879,231) US 4,882,279, US 4,885,242, US 4,895,800, US 4,929,555, US 5,002,876, US
5,004,688, US 5,032,516, US 5,122,465, US 5,135,868, US 5,166,329, WO 00/56903). In the absence of glucose, Pichia pastoris uses methanol as a carbon source which at the same time is a hallmark of a methylotrophic organism. The alcohol oxidase (AOX1) promoter given in SEQ ID NO: 29 controls expression of alcohol oxidase, which catalyses the first step in methanol metabolism. Typically, 30% of the total soluble protein in methanol-induced cells is alcohol oxidase. Several Pichia expression vectors carry the AOXI
promoter and use methanol to induce high-level expression of desired heterologous proteins.
Expression constructs also integrate into the Pichia pastoris genome, creating a transformed and genetically stable host.
Using an expression vector encoding a heterologous pre-protein comprising a signal peptide or a signal peptide with a signal peptidase cleavage site, and a desired protein, methylotrophic yeast strains such as Pichia pastoris strains can be manipulated in order to secrete the desired product into the growth medium from where the secreted protein can be purified. It may be advantageous to produce nucleotide sequences encoding the pre-protein possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the pre-protein occurs in a particular yeast expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding the pre-protein, without altering the encoded amino acid sequences, include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
Using a vector comprising the nucleotide sequence encoding the pre-protein that is competent for expression, e.g. operably linked to a promoter or promoter element and to a terminator or terminator element, as well as to sequences required for efficient translation, the host organism is transformed with a vector and transformants are selected.
Transformants are then analysed with respect to the yield of recombinant protein secreted into the growth medium. Transformants secreting the highest quantities of enzymatically active recombinant protein are selected. Thus, transformants secreting active bovine pancreatic desoxyribonuclease I with the highest specific activity are selected.
On the one hand, expression yield is dependent on proper targeting of the desired product, e.g. to the secretory pathway by means of a signal peptide such as the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. On the other hand, expression yield can be increased by increasing the dosage of the gene encoding the desired product, i.e. the copy number of the expression construct in the host organism is amplified. One way to accomplish this is by multiple transformation of an expression vector encoding the desired product. Another way is to introduce the gene encoding the desired product into the host organism using a first and a second expression vector, whereby the second expression vector is based on a selectable marker which differs from the selectable marker used in the first expression vector. The second expression vector encoding the same desired product can even be introduced when the host organism already carries multiple copies of a first expression vector (US 5,324,639; Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490; Vedvick, T., et al., J. Ind.
Microbiol. 7 (1991) 197-201; Werten, M.W., et al., Yeast 15 (1999) 1087-1096).
Secretion of expressed bovine pancreatic desoxyribonuclease I into the growth medium directs the mature recombinant protein to the extracytoplasmic space from where it diffuses into growth media. Thus, methylotrophic yeast grown in liquid culture secretes bovine pancreatic desoxyribonuclease I into the liquid growth medium, i.e. the liquid culture medium. This allows a. very efficient separation of yeast biomass from the recombinant protein using, e.g. filtration techniques. As a result, bovine pancreatic desoxyribonuclease I purified from this source is very efficiently freed from other enzyme activities such as RNase or protease activities.
High specific enzymatic activity also depends on the structure of bovine pancreatic desoxyribonuclease I. In order to bring about correct structure of a eukaryotic protein, processes like protein folding, the formation of intramolecular disulfide bonds or glycosylation can be involved. It is known that methylotrophic yeast as a eukaryotic host organism for recombinant expression is capable of glycosylating heterologous proteins. It is presumed that recombinant bovine pancreatic desoxyribonuclease I secreted by methylotrophic yeast is glycosylated. Furthermore it might well be possible that in addition disulfide bonds are formed in the course of the secretory pathway of the methylotrophic yeast.
It was surprisingly found that when bovine pancreatic desoxyribonuclease I is expressed and secreted by methylotrophic yeast into the growth medium, this leads to a pancreatic protein with desoxyribonuclease activity, whereby the specific desoxyribonuclease activity of the purified pancreatic protein is very high.
Thus, according to the invention, there is provided a method to produce a bovine pancreatic protein with desoxyribonuclease activity, comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and whereby the bovine pancreatic protein purified in step (d) is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein.
Thus, there is provided a method to produce a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein purified in step (d), comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium.
The method therefore results in a purified bovine pancreatic protein that is bovine pancreatic desoxyribonuclease I, expressed as a heterologous pre-protein in a methylotrophic yeast strain and secreted as a mature protein into the growth medium.
Therefore, in a very preferred embodiment of the invention, the amino acid sequence of the bovine pancreatic protein is SEQ ID NO: 1, that is a nucleotide sequence comprising preferred codons of methylotrophic yeast.
Yeast-derived as well as non-yeast-derived eukaryotic signal peptides other than those particularly mentioned can be used for the same purpose. Although the signal peptides might not be cleavable by the signal peptidase, a signal peptidase cleavage peptide can be inserted into the pre-protein amino acid sequence, that is between the amino acid sequence of the signal peptide and the amino acid sequence of the bovine pancreatic desoxyribonuclease I polypeptide. Therefore, in yet another very preferred embodiment of the invention, the signal peptide contains a signal peptidase cleavage site which is located directly adjacent to the first amino acid of the bovine pancreatic protein.
Very preferred signal peptides are the signal peptides of the pre-proteins in SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. Therefore, in another very preferred embodiment of the invention, the amino acid sequence of the expressed pre-protein is selected from the group consisting of (a) SEQ ID NO: 2, (b) SEQ ID NO: 3, and (c) SEQ ID NO: 4. Thus, the vector encodes the amino acid sequences for bovine pancreatic desoxyribonuclease I
pre-proteins that enter the secretory pathway when expressed in methylotrophic yeast and particularly in Pichia pastoris.
Translation efficiency of a heterologous protein can be improved by adapting the codons of the nucleotide sequence encoding the heterologous protein according to the preferred codons in the host organism. In yet another very preferred embodiment of the invention, the nucleotide sequence encoding the bovine pancreatic protein is SEQ ID NO:
5. Thus, the nucleotide sequence in SEQ ID NO: 5 consists of codons that are preferred in methylotrophic yeast, particularly in Pichia, yet more particularly in Pichia pastoris.
In a preferred embodiment of the invention, the nucleotide sequence encoding the pre-protein consists of the nucleotide sequence encoding the signal peptide fused to the nucleotide sequence encoding the bovine pancreatic protein. In a very preferred embodiment of the invention, the nucleotide sequence encoding the signal peptide is selected from the group consisting of (a) SEQ ID NO: 6, (b) SEQ ID NO: 7, and (c) SEQ ID
NO: 8. SEQ ID NO: 6 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the native bovine pancreatic DNase I pre-protein. SEQ ID NO:
7 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the native bovine pancreatic DNase I pre-protein and an additional signal peptidase cleavage site. SEQ
ID NO: 8 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the a-factor from Saccharomyces cerevisiae. This signal .peptide is a bipartite signal peptide. Therefore, in yet another very preferred embodiment of the invention, the nucleotide sequence encodes a pre-protein selected from the group consisting of (a) SEQ
ID NO: 2, (b) SEQ ID NO: 3, and (c) SEQ ID NO: 4. Moreover, many sources of signal peptides are well known to those skilled in the art. In general, the nucleotide sequence encoding the pre-protein N-terminus of essentially any secreted protein is a potential preferred nucleotide sequence encoding the signal peptide of the bovine pancreatic desoxyribonuclease I pre-protein of the present invention.
In yet a further preferred embodiment of the invention, the nucleotide sequence encoding the pre-protein is operably linked to a promoter or promoter element.
It is also preferred that the promoter or the promoter element stimulates in the methylotrophic yeast strain transcription of the nucleotide sequence that encodes the pre-protein, to which the promoter or the promoter element is operably linked.
Very preferred is a promoter or promoter element from Pichia pastoris, even more preferred is the Pichia pastoris AOXl promoter given in SEQ ID NO: 29. It is also preferred that in addition the nucleotide sequence that encodes the pre-protein is operably linked with a terminator sequence that directs termination of transcription in the methylotrophic yeast strain. Very preferred is a terminator from Pichia pastoris, even more preferred is the Pichia pastoris AOX1 terminator.
In yet a further preferred embodiment of the invention, the vector is a plasmid capable of being replicated as an episome in the methylotrophic yeast strain. Thus, the preferred plasmid is a circular nucleic acid molecule that comprises an origin of replication directing replication of the episome in the methylotrophic yeast strain. Moreover, the plasmid comprises a selectable marker that is expressed in the methylotrophic yeast strain, whereby the selectable marker allows to select for the presence of the plasmid in the methylotrophic yeast strain. A very preferred selectable marker is a Zeocin"m resistance gene, that is the native form or a genetically engineered variant of the Sh ble gene from Streptoalloteichus hindustanus (Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009; Carmels, T., et al., Curr. Genet. 20 (1991) 309-314). Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418 (Southern, P.J., and Berg, P., J. Mol. Appl. Genet. 1 (1982) 327-341). An example for such a selectable marker is an aminoglycoside phosphotransferase gene.
In yet a further preferred embodiment of the invention, an artificial chromosome capable of being replicated in the methylotrophic yeast strain contains the vector.
Thus, the preferred artificial chromosome is a linear nucleic acid molecule that comprises at least one origin of replication, a centromere and terminal telomeres, thereby controlling replication, integrity and mitotic/meiotic distribution of the artificial chromosome in the methylotrophic yeast strain. Moreover, the vector that is contained in the artificial chromosome comprises a selectable marker that is expressed in the methylotrophic yeast strain and that allows to select for the presence of the vector in the artificial chromosome that is replicated in the methylotrophic yeast strain. A very preferred selectable marker is a Zeocin"' resistance gene, that is the native form or an artificial variant of the Sh ble gene from Streptoalloteichus hindustanus. Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418. An example for such a selectable marker is an aminoglycoside phosphotransferase gene.
In yet a further preferred embodiment of the invention, a chromosome of the methylotrophic yeast strain contains the vector. It is very preferred that the vector has a nucleotide sequence identical to a chromosomal sequence, thus allowing integration of the vector into the host chromosome by site-specific recombination. To this end, the Pichia pastoris AOX1 locus is even more preferred as a locus for integration the host chromosome by site-specific recombination. It is also very preferred that, the vector comprises a selectable marker that is expressed in the methylotrophic yeast strain and that allows to select for the presence of the vector in the methylotrophic yeast strain. A
very preferred selectable marker is a Zeocin' resistance gene, that is the native form or an artificial variant of the Sh ble gene from Streptoalloteichus hindustanus. Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418. An example for such a selectable ' marker is an aminoglycoside phosphotransferase gene.
The person skilled in the art is aware of the fact that the yield of secreted bovine pancreatic protein obtainable from growth medium, such as liquid growth medium, can be increased when the number of copies of the nucleotide sequence encoding the pre-protein from which the bovine pancreatic protein is expressed and secreted is increased.
Thus, the yield of secreted bovine pancreatic protein obtainable from growth medium can be increased when number of copies of the vector in the genome of the methylotrophic yeast strain is increased. For example, the copy number of the vector can be increased by subjecting the methylotrophic yeast strain to repeated transformations of the vector and repeated selection rounds using increasing concentrations of the selective agent against which the selective marker comprised in the vector confers resistance (US 5,324,639;
Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490;
Vedvick, T., et al., J. Ind. Microbiol. 7 (1991) 197-201).
The person skilled in the art is also aware of the fact that repeated transformations can be carried out using more than one vector. For example, repeated transformations can be carried out using a first and a second vector, whereby the first and the second vector encode the same pre-protein, whereby in the first and in the second vector the nucleotide sequence encoding the pre-protein is operably linked to a promoter or promoter element, whereby the same bovine pancreatic protein is expressed and secreted, and whereby the first and the second vector confer resistance to a first and a second selection marker.
An example for a first selective marker is the Sh ble gene, that is the ZeocinTM resistance gene (Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009; Carmels, T., et al., Curr.
Genet. 20 (1991) 309-314). The protein encoded by the Sh ble gene binds ZeocinTM
stoichiometrically and with a strong affinity. The binding of ZeocinTM
inhibits its toxic activity thereby selecting for transformants containing the Sh ble gene. It is known to a person skilled in the art that increasing the concentration of ZeocinTM as the selective agent in the medium selects for an increase in the number of copies of the vector expressing the Sh ble gene. It is therefore advantageous to use a vector with the Sh ble gene as a selectable marker to generate by repeated transformation multiple transformants of the methylotrophic yeast strain containing multiple copies of the vector. It is furthermore advantageous that transformations are repeated and selection for even more resistant transformants is repeated until for the transformed methylotrophic yeast strain no further increase of the level of resistance to ZeocinTM is obtained anymore or no further increase of the ZeocinTM concentration in the selection medium is possible anymore.
In case a first and a second vector are used, an example for a second selection marker is resistance against aminoglycoside antibiotics (Southern, P.J., and Berg, P., J. Mol. Appl.
Genet. 1 (1982) 327-341) such as G418. Thus, an exemplarily second vector expresses a resistance gene that confers resistance against G418. For example, there are several aminoglycoside phosphotransferases known to the art that confer resistance to aminoglycoside antibiotics (van Treeck, U., et al., Antimicrob Agents Chemother. 19 (1981) 371-380; Beck, E., et al., Gene 19 (1982) 327-336). The aminoglycoside phosphotransferase I (APH-I) enzyme has the ability to inactivate the antibiotic G418 and is an established selectable marker in yeast (Chen, X.J., and Fukuhara, H., Gene (1988) 181-192).
Thus, for the purpose of further increasing the dosage of the nucleotide sequence encoding the pre-protein from which the bovine pancreatic protein is expressed and secreted, the second vector is advantageously used for further rounds of transformation and selection, whereby in this case a preferred selective agent is G418 and whereby for transformation the methylotrophic yeast strain transformed with the first vector is used.
In yet a further preferred embodiment of the invention, the methylotrophic yeast strain is a Hansenula, Pichia, Candida or Torulopsis species. In a very preferred embodiment of the invention, the methylotrophic yeast strain is selected from the group consisting of Pichia pastoris, Hansenula polymorpha, Candida boidinii and Torulopsis glabrata.
Even more preferred Pichia pastoris strains are deposited at the American Type Culture Collection (ATCC) with the accession numbers 201178, 201949, 204162, 204163, 204164, 204165, 204414, 204415, 204416, 204417, 20864, 28485, 34614, 60372, 66390, 66391, 66392, 66393, 66394, 66395, 76273, 76274, and 90925.
Yet, an even more preferred methylotrophic yeast strain is the Pichia pastoris strain with the American Type Culture Collection accesssion number 76273 or a derivative thereof.
Even more preferred Hansenula polymorpha strains are deposited at the American Type Culture Collection with the accession numbers 14754, 200499, 200500, 200501, 200502, 200503, 200504, 200505, 200506, 200507, 200508, 200509, 200510, 200511, 200512) 200513, 200838, 200839, 201322, 204205, 22023, 26012, 34438, 36669, 38626, 44954, 44955, 46059, 48180, 58401, 62809, 64209, 66057, 76722, 76723, 76760, 90438, 96694, 96695, MYA-335, MYA-336, MYA-337, MYA-338, MYA-339, and MYA-340.
Even more preferred Candida boidinii strains are deposited at the American Type Culture Collection with the accession numbers 18810, 201209, 20432, 26175, 32195, 32929, 36351, 38256, 38257, 44637, 46498, 48180, 56294, 56507, 56897, 60364, 62807, 90439, 90441, 96315, and 96926.
Even more preferred Torulopsis "glabrata strains are deposited at the American Type Culture Collection with the accession numbers 15126, 15545, 2001, 22019, 26512, 28226, 28290, 32312, 32554, 32936, 34147, 34449, 36909, 38326, 4135, 46433, 48435, 58561, 66032, 750, and 90030.
A person skilled in the art is familiar with the purification of bovine pancreatic desoxyribonuclease I by means of chromatography (Funakoshi, A., et al., J.
Biochem.
(Tokyo) 88 (1980) 1113-1138; Paudel, H.K., and Liao, T.H., J. Biol Chem. 261 (1986) 16006-16011; Nefsky, B., and Bretscher, A., Eur. J. Biochem. 179 (1989) 215-219). It is _19-preferred, however, that bovine pancreatic desoxyribonuclease I which has been secreted by a transformed methylotrophic yeast strain into the growth medium is purified using ion exchange chromatography. Very preferred as a solid phase for ion exchange chromatography is a cation exchanger. In a preferred embodiment of the invention, Bovine pancreatic desoxyribonuclease I binds to the cation exchanger in the presence of a bivalent cation and acetate at low conductivity of the liquid phase, that is in a binding buffer of low conductivity. A preferred bivalent cation is Mg2+, Cat+, or Mn2+. Preferred for low conductivity is the range of 0.5 - 10 mS/cm. Very preferred for low conductivity is the range of 1- 5 mS/cm. Even more preferred for low conductivity is the range of 3 mS/cm. It is also preferred that the binding buffer comprises a protease inhibitor.
Furthermore, it is preferred that the binding buffer has an acidic pH. A
preferred pH is in the range between 4.5 and 6.9. Even more preferred is a pH of 5Ø Other proteins can be removed almost completely by washing the solid phase repeatedly with the binding buffer of low conductivity, whereby bovine pancreatic desoxyribonuclease I remains bound to the solid phase, that is the cation exchanger. In another preferred embodiment of the invention, elution of bovine pancreatic desoxyribonuclease I is accomplished using an elution buffer with high conductivity in the presence of a bivalent cation and acetate, whereby a small elution volume is advantageous. A preferred bivalent cation is Mgt , Ca2t, or Mn2t. Also preferred is a concentration of 0.3 M NaCl in the elution buffer. It is furthermore preferred that the elution buffer comprises a protease inhibitor.
Furthermore, it is preferred that the elution buffer has an acidic pH. A preferred pH is in the range between 4.5 and 6.9. Even more preferred is a pH of 5Ø Preferred for high conductivity. is the range of 10 - 60 mS/cm. Very preferred for high conductivity is the range of 20 - 50 mS/cm. Even more preferred for high conductivity is the range of 30 - 40 mS/cm. It is further preferred to repeat the washing of the solid phase with binding buffer, that is a buffer with low conductivity as described above, in order to achieve a purity higher than about 95% of the eluted bovine pancreatic desoxyribonuclease I. Purity is to be tested by means of SDS PAGE, whereby gels are stained using Coomassie Blue. Also very preferred is a further purification step consisting of affinity chromatography using heparin sepharose.
Using this further step, a person skilled in the art is able to achieve about 98% purity of bovine pancreatic desoxyribonuclease I, to be tested by means of SDS PAGE, whereby gels are stained using Coomassie Blue. The specific desoxyribonuclease activity of the affinity-purified bovine pancreatic protein is at least 6,000 units per mg of protein.
Yet another preferred embodiment of the invention is a Pichia pastoris strain with a chromosome that contains a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, operably linked with the Pichia pastoris AOX1 promoter according to SEQ ID NO: 29 or a promoter element thereof, whereby the nucleotide sequence that encodes the pre-protein is SEQ ID
NO: 7 or SEQ ID NO: 8, fused to SEQ ID NO:5.
Yet another preferred embodiment of the invention is a bovine pancreatic protein with a specific desoxyribonuclease I activity of at least 6,000 units per mg of protein, obtainable by the method comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic *yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, and whereby the bovine pancreatic protein has desoxyribonuclease activity.
Another very preferred embodiment of the invention is a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein that retains at least 50% of its specific desoxyribonuclease activity after heat incubation at 75 C for 60 min, whereby during heat incubation the bovine pancreatic protein is dissolved in a storage buffer containing 20 mM TrisHCl, 2 mM MgC12: 4 mM CaC12i 50% glycerol; pH 7.6.
Yet another preferred embodiment of the invention is the use of a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein for hydrolysing DNA.
Yet another preferred embodiment of the invention is a kit of parts containing a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein and a reaction buffer comprising a divalent cation. Yet another very preferred embodiment of the invention is the kit of parts, whereby the bovine pancreatic protein is dissolved in a storage buffer containing water, glycerol, a protease inhibitor, and a divalent cation, whereby the reaction buffer contains a divalent cation contains selected from the group consisting of Mg2+, Ca2t and Mn2+.
The method of the present invention presents an alternative to the purification of bovine pancreatic desoxyribonuclease I. Furthermore, it allows the production and purification of an active bovine pancreatic desoxyribonuclease I enzyme with a very high specific activity.
The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
Description of the Figures Figure 1 Map of the plasmid pDNASE-1 which is a derivative of the commercially available plasmid pPICZaA (Invitrogen) that confers resistance to ZeocinTM. The insert denoted "DNAseI" is the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I protein (SEQ
ID NO: 5) that is fused to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae (SEQ ID NO: 8). "AOX1-Prom" denotes the Pichia pastoris AOXI promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Figure 2 Map of the plasmid pDNASE-2 which is a derivative of the commercially available plasmid pPIC9K (Invitrogen) that confers resistance to G418.
The insert denoted "DNAseI" is the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I protein (SEQ ID NO: 5) that is fused to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae (SEQ ID NO: 8). "AOXI-Prom denotes the Pichia pastoris AOX1 promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Figure 3 Map of the plasmid pDNASE-4 which is a derivative of the commercially available plasmid pPICZaA (Invitrogen) that confers resistance to ZeocinTM.. The insert denoted "Sig-DNAseI" is the fusion of the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I
protein (SEQ ID NO: 5) with the nucleotide sequence encoding the native bovine pancreatic' desoxyribonuclease I signal peptide sequence and an additional signal peptidase cleavage site (SEQ ID NO: 7). "AOX1-Prom" denotes the Pichia pastoris AOX1 promoter, "Term" denotes the .30 Pichia pastoris AOX1 terminator.
Figure 4 Map of the plasmid pDNASE-6 which is a derivative of the commercially available plasmid pPIC9K (Invitrogen) that confers resistance to G418.
The insert denoted "Sig-DNAseI" is the fusion of the synthetic DNA
sequence encoding the mature bovine secreted desoxyribonuclease I
protein (SEQ ID NO: 5) with the nucleotide sequence encoding the native bovine pancreatic desoxyribonuclease I signal peptide sequence and an additional signal peptidase cleavage site (SEQ ID NO: 7). "AOXI-Prom" denotes the Pichia pastoris AOX1 promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Exam lpeI
Synthesis of a yeast-adapted nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I protein Generally, standard methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL
Press, 2001.
In order to optimise each codon for the use in yeast, the encoding vector was synthesised de novo. The sequence of the mature bovine pancreatic desoxyribonuclease I
protein is given in SEQ ID NO: 1 and consists of 260 amino acids. Back-translation resulted in a nucleotide sequence of 783 base pairs including a stop codon. The yeast-adapted coding sequence is given in SEQ ID NO: 5. The coding sequence was divided into 18 DNA
oligonucleotides having a length of between 42 and 72 nucleotides. The single-stranded DNA
oligonucleotides were designed as a series of alternating coding strand and non-coding strand fragments, having complementary 5' and 3' overlaps with the neighbouring fragments. The DNA oligonucleotides used in this manner are given in SEQ ID
NO: 9, SEQ
ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID
NO:
15, SEQ ID NO. 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. The overlapping region was chosen such that unspecific binding during an annealing reaction was largely suppressed. The DNA oligonucleotides representing the 5' end and 3' end of the sequence encoding SEQ ID NO: 1 included restriction endonuclease cleavage sites located upstream and downstream of the coding sequence, in order to facilitate insertion of the artificial nucleotide sequence into expression vectors. Upstream the 5' end of the sequence encoding SEQ ID NO: 1, an Xho I cleavage site and the codons for two amino acids of the C-terminus of the c -factor signal peptide from Saccharomyces cerevisiae were added. Downstream of the stop codon, i.e. the 3' end of the sequence encoding SEQ ID NO: 1, Not I and Bgl II cleavage sites were added.
Three larger DNA fragments were synthesised separately from DNA
oligonucleotides by means of the polymerise chain reaction (PCR). The first reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID
NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14. The second reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID
NO:
18, SEQ ID NO: 19, and SEQ ID NO: 20. The third reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID
NO:
24, SEQ ID NO: 25, and SEQ ID NO: 26. In the course of PCR, in each cycle overlapping termini were annealed and complementary DNA strands were synthesised.
Therefore, the DNA oligonucleotides were enlarged stepwise until the final length of the fragment was reached. To this end, the annealing temperature was chosen according to the requirements of the overlapping regions, i.e. the region with the lowest melting temperature determined the annealing temperature. During subsequent cycles, the final fragment was amplified.
By means of agarose gel electrophoresis the three larger DNA fragments were separated from any by-products. Gel bands corresponding to the desired fragments were excised and DNA was isolated from agarose blocks using the "QlAquick Gel Extraction Kit"
(Qiagen catalogue no. 28704). The three larger DNA fragments were then combined in a further PCR in the same fashion as described above, in order to synthesise the complete vector encoding the mature bovine pancreatic desoxyribonuclease I protein. The first five PCR
cycles were made with the three larger DNA fragments without any further primers added.
Again, the annealing temperature was chosen according to the requirements of the overlapping regions, i.e. the region with the lowest melting temperature.
Subsequently, two DNA oligonucleotides representing the termini of the complete artificial nucleotide sequence were added. The annealing temperature was raised according to the requirements of the added primers, i.e. the primer with the lowest melting temperature determines the annealing temperature. The complete artificial nucleotide sequence was amplified in the course of 25 PCR cycles.
The complete DNA fragment encoding the mature bovine pancreatic desoxyribonuclease I
protein was subsequently inserted into a cloning vector and propagated in E.
coli using conventional techniques (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001). The nucleotide sequence of the complete DNA
fragment was verified by sequencing.
n. e ' Cloning of the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
In order to provide a nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein, two complementary single-stranded DNA oligonucleotides were synthesised. As in Example 1, the codons were designed according to the preferred codon usage in methylotrophic yeast. The DNA
oligonucleotides used are given in SEQ ID NO: 27, SEQ ID NO: 28. The 5' ends of the DNA
oligonucleotides were designed such that the annealed, i.e. double-stranded nucleic acid would have, terminal overhangs identical to the overhangs which would have been created by cleavage of restriction endonucleases Sfu I and Xho I. The orientation of the overhangs is given with respect to the coding strand with the Sfu I site being located at its 5' end and the Xho I site being located at its 3' end. Upstream of the coding sequence an optimal Kosak-sequence has been inserted, to facilitate efficient initiation of translation in the host organism.
Of each of the two DNA oligonucleotides 5 pg were dissolved in 10 mM TrisHCl pH 7.5, 10 mM MgC12, 50 mM NaCl, 1 mM Dithiothreitol and heated at 100 C for 5 minutes, so that unwanted secondary structures and irregular hybridisation products were broken up.
Subsequently, hybridisation was allowed to take place by slowly cooling the mixture to room temperature. The double-stranded nucleic acid was analysed in an agarose gel and directly used in a ligation reaction with the expression vector pPICZA
(Invitrogen, Carlsbad, CA, USA) which was linearised before with Sfu I and Xho 1. The resulting vector which carried the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was subsequently analysed by restriction enzyme digestion and agarose gel electrophoresis as well as by sequencing.
Ex,rple 3 Cloning of the artificial vector encoding mature bovine pancreatic desoxyribonuclease I in various expression vectors Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The artificial DNA fragment encoding the mature bovine pancreatic desoxyribonuclease I
that was generated from PCR fragments (see Example 1) was excised with Xho I
and Bgl II
(Roche Diagnostics GmbH). The fragment was isolated using the "QlAquick Gel Extraction Kit" according to the instructions of the manufacturer.
Case 1: The fragment was ligated into the pPICZA vector fusing the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I to the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I
pre-protein (see Example 2). Before the ligation reaction, the vector was similarly cleaved with Xho I and Bgl II, and isolated.
Case 2: The fragment was ligated into the pPICZaA vector fusing the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae. Before the ligation reaction, the vector was similarly cleaved with Xho I and Bgl II, and isolated.
The cloning procedure followed in Case 1 inserted a linker sequence - encoding Leucine-Glutamic acid-Lysine-Arginine into the reading frame between the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the sequence encoding the mature protein. The Leucine-Glutamic acid sequence was inserted by virtue of the Xho I site (CTCGAG). The Lysine-Arginine sequence is known to represent a KEX-2 signal peptidase cleavage site, needed to cleave off the signal peptide from the pre-protein in the course of the secretory pathway. The nucleotide sequence for the Lysine-Arginine sequence is comprised in SEQ ID NO: 7 that corresponds to the signal peptide amino acid sequence in SEQ ID NO: 3. The cloning procedure followed in Case 2 inserted the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I
directly and in-frame after the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae.
In both cases, the nucleotide sequence encoding the recombinant pre-protein were under the control of the P. pastoris AOX-1 promoter (SEQ IN NO.: 29) which is inducible by methanol.
Construction was accomplished by joining in a total volume of 10 d 20 ng of linearised vector fragment (in a volume of 1 l), 100 ng of PCR fragment (in 3 1), and incubation overnight at 16 C in the presence of T4 DNA ligase (Roche Diagnostics GmbH) according to the instructions of the manufacturer. 5 p1 of the ligation preparation were subsequently used to transform competent (Hanahan, 1983) E. coli XLIBlue cells (Stratagene), in a total volume of 205 l. Following incubation on ice for 30 min, cells were heat-shocked at 42 C
for 90 sec. Subsequently, cells were transferred into 1 ml LB medium and incubated for 1 h at 37 C to allow for expression of selection- markers. Aliquots were plated afterwards on LB
plates containing 100 g/ml Zeocin and incubated for 15 h at 37 C. Resistant clones were picked, plasmids were isolated (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001) and tested by means of restriction analysis as well as sequence analysis. Construct clones verified to be free of errors and cloning artifacts were selected. The expression vector harbouring bovine pancreatic desoxyribonuclease I with the a-factor signal peptide from Saccharomyces cerevisiae was designated pDNASE-1, the expression vector harbouring bovine pancreatic desoxyribonuclease I with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was designated pDNASE-4.
Example 4 Transformation of Pichia pastoris with pDNASE-1 and pDNASE-4 Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The host strains used were Pichia pastoris X-33, GS115, KM71H and SMD1168 (Invitrogen). Preferred strains were X-33 and KM71H. Transformation was aimed at stably integrating expression constructs into the genome of the host organism.
Initially, 5 ml YPD medium (YPD = yeast peptone dextrose; Invitrogen) was inoculated with a P. pastoris colony and pre-cultured on a shaker overnight at 30 C. To prepare transformation-competent cells, 100. l of the pre-culture were added as inoculum to 200 ml of fresh YPD medium and grown until an OD600nm of between 1.3 and 1.5 was reached. The cells were centrifuged at 1,500 x g for 5 min and resuspended in 200 ml ice cold (0 C) sterile water. The cells were centrifuged again at 1,500 x g for 5 min and resuspended in 100 ml ice cold sterile water. The cells were centrifuged one more time at 1,500 x g for 5 min and resuspended in 10 ml ice cold 1 M sorbitol (ICN). The cells prepared in this way were kept on ice and used for transformation immediately.
The expression vectors pDNASE-1 and pDNASE-4 to be used for transformation were linearised using the Sac I restriction endonuclease (Roche Diagnostics GmbH), precipitated and resuspended in water. Transformation was accomplished by eectroporation using a "Gene Pulser IITM" (BioRad). For. a transformation setting, 80 l P. pastoris cells in 1 M
sorbitol solution were mixed gently with 1 g of linearised expression vector DNA and transferred into an ice cold cuvette which was then kept on ice for 5 min.
Subsequently, the cuvette was transferred into the Gene Pulser. Electroporation parameters were 1 kV, 1 kQ
and 25 F. Following eectroporation, 1 ml 1 M sorbitol solution was added to the cell suspension was subsequently plated onto YPDS plates (YPDS = yeast peptone dextrose sorbitol; Invitrogen) containing 100 g/ml ZeocinTM (Invitrogen), with 100-150 l of cell suspension being spread on a single plate. YPDS plates were incubated at 30 C
for 2-4 days.
Yeast clones were transferred onto gridded minimal dextrose plates. Colonies from these plates were picked and separately resuspended in sterile water. The cells were digested with 17.5 units of lyticase (Roche Diagnostics GmbH) for 1 h at 30 C and afterwards frozen for 10 min at -80 C. By means of PCR, the presence of the expression cassettes of pDNASE-1 and pDNASE-4 was verified. The term "expression cassette" denotes a nucleotide sequence encoding the bovine pancreatic desoxyribonuclease I pre-protein, operably linked to the AOX1 promoter and the AOX1 terminator, whereby the expression cassette is derived from the respective pDNASE vector used for transformation. As for vectors containing an expression cassette, the terms "vector" and "expression vector" are synonyms.
Positive clones, i.e. clones that were tested positively for the presence of complete expression cassettes stably integrated into the genome were used for further characterisation of bovine pancreatic desoxyribonuclease I expression.
Additionally, control transformations were made with the recipient Pichia pastoris X33 strain using the pPICZaA vector. Positive clones were obtained and verified in a similar fashion.
Example 5 Expression and secretion of recombinant bovine pancreatic desoxyribonuclease I, analysis of pre-proteins with different signal peptides Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
A set of positive clones (usually 20-30) transformed with pDNASE-1 and pDNASE-4 (see Example 4) were grown as shaking cultures overnight, each in 3 ml BMGY medium.
(BMGY = buffered glycerol-complex medium; Invitrogen). Afterwards, the OD600nm values of the cultures were determined before they were passaged into shaking flasks, each containing 10 ml BMMY medium (Invitrogen) at pH 3. Pre-cultures were used as inoculum to result each in an OD600nm of 1. The cultures were kept on a shaker at 30 C. In parallel, positive control clones were cultured under the same conditions.
BMMY (BMMY = buffered methanol-complex medium;) medium comprises methanol.
(Mallinckrodt Baker B.V.) which is an inductor of the AOX-1 promoter that controls.
transcription of the recombinant bovine pancreatic desoxyribonuclease I
sequences inserted into the expression vectors.
Samples of 500 l were taken from the shaking flask in 24 h intervals over a total time of 72 h. When a sample aliquot was removed, the culture was also fed with 0.5%
methanol.
Samples of the supernatant growth medium were tested for desoxyribonuclease enzymatic activity.
Example 6 Analysis of expression of recombinant bovine pancreatic desoxyribonuclease I
Of the sample aliquots obtained as described in Example S firstly the OD600nn, was determined. Subsequently the cells were pelleted by centrifugation and the supernatant was saved. Desoxyribonuclease activity was measured in the undiluted supernatant as well as in a 1:10 dilution (Example 10).
While control clones transformed with the pPICZaA vector did not lead to any measurable desoxyribonuclease activity in the medium, Pichia strains transformed with both pDNASE-1 and pDNASE-4 showed desoxyribonuclease activity due to bovine pancreatic desoxyribonuclease I secreted into the growth medium, i.e. the culture medium.
It could therefore be concluded that that expression of a recombinant pre-protein comprising either the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein enables secretion of an active enzyme having desoxyribonuclease activity.
Regarding the yield of secreted mature protein, i.e. the desired bovine pancreatic desoxyribonuclease I, there were no obvious differences between the strains expressing the pre-protein with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein with the a-factor signal peptide from Saccharomyces cerevisiae.
Example 7 Increasing expression yield by multiple transformation and increased ZeocinTM
concentration Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The yeast clones transformed with the expression vectors pDNASE-1- and pDNASE-4 that were found to produce the highest desoxyribonuclease activities in supernatant media were subjected to repeated electroporation using the same expression vector as previously.
Conditions for electroporation were as described in Example 4 with the exception that YPDS plates contained ZeocinT"' at increased concentrations, that is between 1,000 and 2,000 Vg/ml. The concentration of the antibiotic was increased in order to select for transformants having incorporated into their genome multiple copies of the respective expression vector. Yeast clones with increased resistance to the antibiotic were transferred onto gridded minimal dextrose plates. As already described in Example 5, pre-cultures were made from individual yeast clones and expression was measured by determining the desoxyribonuclease enzymatic activity secreted into the growth medium as described in Example 6. Individual clones were found that produced an increased amount of desoxyribonuclease activity. This was the case for yeast transformants expressing both types of recombinant pre-protein, i.e. pre-protein comprising either the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. On the average, desoxyribonuclease activity measured in the supernatant of Pichia strains repeatedly transformed with pDNASE-1- or pDNASE-4 was between twice to three times as high compared to the respective precursor strains that had undergone only a single transformation.
Regarding the yield of secreted mature protein, there were no obvious differences between the strains expressing the pre-protein with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein with the a-factor signal peptide from Saccharomyces cerevisiae.
Example 8 Increasing expression yield by means of introducing a different expression vector allowing to apply further selection pressure Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
From the expression vectors pDNASE-1 and pDNASE-4 the expression cassette consisting of a part of the AOX-1 promoter and the reading frame for the respective pre-protein (see Figures 1 and 3) was excised using restriction endonucleases Sac I and Xba I
(Roche Diagnostics GmbH). The resulting cleavage products were separated by agarose gel electrophoresis. In the case of pDNASE-1, a fragment having the size of 1765 bp was excised and isolated using the "QlAquick Gel Extraction Kit" (Qiagen). In the case of pDNASE-4, a fragment having the size of 1560 bp was excised and isolated using the "QIAquick Gel Extraction Kit"
(Qiagen). In both fragments, the Xba I overhang was converted to a blunt end using Klenow polymerase (Roche Diagnostics GmbH).
The vector pPIC9K (Invitrogen) was cleaved using restriction endonucleases Sac I and Not I (Roche Diagnostics GmbH). The resulting cleavage products were separated by agarose gel electrophoresis. A fragment with a size of 8956 bp was excised and isolated using the "QlAquick Gel Extraction Kit" (Qiagen). The Not I overhang was converted to a blunt end using Klenow polymerase (Roche Diagnostics GmbH). The expression cassettes prepared from pDNASE-1 and pDNASE-4 were inserted separately. Ligation, bacterial transformation and cloning procedures were performed as described in Example 3 with the exception that transformed bacterial clones were selected on LB plates containing 100 pg/ml of the antibiotic ampicillin. Clones were verified by means of restriction analysis and sequencing. The pPIC9K-derived expression vector harbouring bovine pancreatic desoxyribonuclease I with the a-factor signal peptide from Saccharomyces cerevisiae was designated pDNASE-2, the pPIC9K-derived expression vector harbouring bovine pancreatic desoxyribonuclease I with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was designated pDNASE-6.
Using the pPIC9K-derived expression vectors, resistance to the antibiotic G418 was introduced. Among the Pichia pastoris ZeocinTM-resistant transformants having incorporated into their genome multiple copies of the pDNASE-1 and pDNASE-4 expression vectors those were selected that secreted into the growth medium the highest amounts of desoxyribonuclease activity. Clones containing multiple copies of pDNASE-1 were transformed with pDNASE-2 and clones containing multiple copies of pDNASE-were transformed with pDNASE-6. Expression vectors to be used were linearised using the Sal I restriction endonuclease (Roche Diagnostics GmbH). 1 g of the respective linearised expression vector was used for transformation which was performed as described in Example 4. Following electroporation, the cells were kept at 4 C in 1 M
sorbitol for a period of between 1 and 3 days, in order to allow the cells become resistant to the antibiotic. The cell suspension was plated onto YPDS plates (Invitrogen) containing 1, 2 and 4 mg/ml G418 (Roche Diagnostics GmbH), with 100-200 l of cell suspension being spread on a single plate. YPDS plates were incubated at 30 C for 3-5 days.
Yeast clones were transferred onto gridded minimal dextrose plates. Clones originating from YPDS
plates with the highest G418 concentration were preferentially transferred. Selected clones were characterised further as described in Example 4.
Multiply transformed and verified Pichia clones carrying multiple copies of expression vectors conferring Zeocin"" resistance as well as the expression vector conferring resistance to G418 were characterised with respect to the amount of desoxyribonuclease activity secreted into the growth medium. Assays were performed as described in Example 5.
Clones harbouring pDNASE-1 and pDNASE-2 constructs were identified which produced an even higher level of secreted desoxyribonuclease enzymatic activity than the precursor clones containing only multiple copies of pDNASE-1 but, not pDNASE-2.
Additionally, clones harbouring pDNASE-4 and pDNASE-6 constructs were identified which produced an even higher level of secreted desoxyribonuclease enzymatic activity than the precursor clones containing only multiple copies of pDNASE-4 but not pDNASE-6. On the average, desoxyribonuclease activity measured in the supernatant of cultures that were transformed with pDNASE-2 or pDNASE-6, i.e. in addition to multiple transformations with pDNASE-1 or pDNASE-4, was found to be about four times as high when compared to the respective precursor strains that had undergone only a single transformation.
Regarding the yield of secreted mature protein, there were no obvious differences between the strains expressing the pre-protein comprising the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein comprising the a-factor signal peptide from Saccharomyces cerevisiae.
Example 9 Purification of recombinant bovine pancreatic desoxyribonuclease I protein from liquid culture supernatant Biomass was removed from the supernatant growth medium by filtration or by centrifugation. Bovine pancreatic desoxyribonuclease I was subsequently purified by means of ion exchange chromatography using a cation exchanger. A cation exchanger that was used with success was SP sepharose. Bovine pancreatic desoxyribonuclease I was bound to the cation exchanger at low conductivity of the liquid phase, that is in a binding buffer of low conductivity. Low conductivity corresponded to a value of conductivity between 2 -3 mS/cm. The binding buffer had a pH of 5.0 and contained 20 mM Ca 2-' acetate and 1 mM PefablocT'". Other proteins were removed by washing the solid phase repeatedly with binding buffer, whereby the bovine pancreatic desoxyribonuclease I remained bound by the solid phase, that is the cation exchanger. Elution of bovine pancreatic desoxyribonuclease I was accomplished using an elution buffer with high conductivity.
High conductivity corresponded to a value of conductivity between 30 40 mS/cm.
The elution buffer had a pH of 5.0 and contained 0.3 M NaCl, 20 mM Ca 2+ acetate and 1 mM
Pefabloc'. The purity of the bovine pancreatic desoxyribonuclease I achieved after this step was higher than about 95% as tested by means of SDS PAGE, whereby gels were stained using Coomassie Blue. The subsequent purification step was affinity chromatography using heparin sepharose to remove RNase activity. The buffer system used was 2 mM Tris/HCJ pH 6.5 with a conductivity 2.1 +/- 0.1 mS/cm. The bovine pancreatic desoxyribonudease I not is bound to the solid phase. Following this step, the purity of the bovine pancreatic desoxyribonuclease I was higher than about 98%
as tested by means of SDS PAGE, whereby gels were stained using Coomassie Blue. The specific desoxyribonuclease activity of the affinity-purified bovine pancreatic desoxyribonuclease I
was higher than or equal to 6;000 units per mg of protein.
Example 10 Assay to determine the specific desoxyribonuclease activity of purified bovine pancreatic desoxyribonuclease I in growth culture supernatant The test for desoxyribonuclease activity in sample aliquots was performed according to Kunitz, M., J. Gen. Physiol. 33 (1950) 349-62 and 363. Calf thymus DNA was dissolved at a concentration of 0.05 mg/ml in a buffer containing 10 mM TrisHCl pH 8.0, 0.1 mM CaC12, 1 mM MgC12. Purified desoxyribonuclease activity-containing growth medium such as culture supernatant was added and the increase of the extinction at 260 nm was photometrically measured over time at 25 C. 1 unit (1 U) corresponds to an extinction increase (DE) of 0.001 per min. Representative results are given in Table 1.
Table 1 Determination of desoxyribonuclease activity in the culture supernatant of three different transformed strains of Pichia pastoris Strain 1 Strain 2 Strain 3 Assayed volume of culture supernatant 0.01 ml 0.007 ml 0.007 ml DE / min 0.0114 0.0133 0.0155 U / ml 1,425 2,375 2,065 Exam 1 Assay to determine the specific desoxyribonuclease activity of purified bovine pancreatic desoxyribonuclease I
The desoxyribonuclease-free reference sample was the sample buffer, that is a mixture of 1 part 1 M sodium acetate pH 5.0, 1 part 50 mM MgSO4 and 8 parts double-distilled water.
For the substrate buffer, calf thymus DNA was dissolved in a buffer containing 5 mM
MgSO4 and 100 mM sodium acetate pH 5.0 and incubated between 24 to 30.hours in a water bath at 37 C. Unsoluble parts were removed by centrifugation for 10 min at 13,000 x g. Substrate buffer contained DNA at a concentration of 0.04 mg/mi.
DNA
content of the supernatant was determined photometrically at 260 nm and, if necessary, the substrate buffer was adjusted with sample buffer to give an extinction value of 0.8.
Substrate buffer was stored for at least 3 days at 4 C before use.
DNase-containing solution with a volume activity of about 10,000 units per ml obtained from purification of bovine pancreatic desoxyribonuclease I according to Example 9 was used for the determination of desoxyribonuclease activity. 5 .d of the desoxyribonuclease-containing solution was diluted with 95 l double-distilled water. Firstly, 2.5 ml substrate buffer was filled into a quartz cuvette with a thickness of 1 cm. Both the substrate buffer and the cuvette were kept at 25 C, measurements were at the same temperature.
The wave length at which measurements were taken was 260 nm. After the photometer was set to zero extinction (reference value) 0.05 nil diluted desoxyribonuclease-containing solution was added and mixed. The increase of the extinction (AE/min) was measured over time.
One unit (1 U) corresponds to the activity that under the conditions as described above leads to an increase of the extinction of 0.001 per min.
The activity per volume given as was calculated as [U / ml] 2,55 x 1,000 x DE/min 0.05 The activity of undiluted bovine pancreatic desoxyribonuclease I preparations was calculated according to the dilution factor applied. It was also generally observed that the units measured using this assay were comparable to those of the Kunitz assay.
Additionally, protein content was measured using the same type of cuvettes as above.
Measurements were taken of purified bovine pancreatic desoxyribonuclease I in sample buffer at temperatures between 20 C and 25 C, at a wave length of 280 nm, with the sample buffer serving as reference.
The protein content was calculated from extinction values (AE280) as [mg protein / ml] = AE280 x 0.796 Each measurement was taken in triplicate. Specific desoxyribonuclease activity in a given volume was then calculated as units per mg of protein. Representative results are given in Table 2.
Table 2 Determination of specific desoxyribonuclease activity of bovine pancreatic desoxyribonuclease I purified from the culture supernatant of three different multiply transformed strains of Pichia pastoris Strain 1 Strain 2 Strain 3 Assayed volume of purified 0.01 ml 0.04 ml 0.04 ml desoxyribonuclease preparation iE / min 0.008 0.011 0.0105 U / ml 99,375 17,266 16,328 AE280 0.099 0.134 0.133 mg of protein / ml 15.8 2.13 2.1 specific desoxyribonuclease activity 6,289 8,106 7,775 Exarnple 12 Thermostability of purified active bovine pancreatic desoxyribonuclease I
Aliquots of purified bovine pancreatic desoxyribonuclease I in a storage buffer containing mM TrisHC1, 2 mM MgC12i 4 mM CaC12, 50% glycerol, pH 7.6 were incubated for 60 min at 55 C, 60 C, 65 C, 70 C, 75 C, and 80 C, whereby each aliquot had a volume of 500 l and contained at least 10,000 units per ml. Each aliquot was kept over the heating period in a fine-regulated (variation limit less than 0.5 C) thermostate block heater.
20 Immediately after the incubation, residual specific desoxyribonuclease activity was measured as activity per volume using the assay as described in 0.
Representative results are tabulated in Table 3. Residual activity per volume after heat treatment is given as a percentage with the activity of an untreated control aliquot being set as 100%. No differences regarding heat stability were found with respect to Pichia yeast strains used for transformation (see e.g. Example 4) or the kind of signal peptides present in the respective pre-protein (see e.g. Examples 3, 5, 6, 7, 8) Table 3 Residual specific desoxyribonuclease activity after heat incubation Temperature Residual specific 91% 86% 73% 58% 52% 46%
desoxyribonuclease activity after 60 min List of References Alberts,-B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing Beck, E., et al., Gene 19 (1982) 327-336 Carmels, T., etal., Curr. Genet. 20 (1991) 309-314 Chen, C.Y., et al., Gene 206 (1998) 181-184 Chen, X.J., and Fukuhara, H., Gene (1988) 181-192 Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009 Funakoshi, A., et al., J. Biochem. (Tokyo) 88 (1980) 1113-1138 Julius, D., et al., Cell 37 (1984) 1075-1089 Kaighn, M.E., In: Tissue culture, methods and applications; Kruse, P. F. &
Patterson, M. K., eds., Academic Press, New York & London, 1973, 54-58 Kunitz, M., J. Gen. Physiol. 33 (1950) 349-62 and 363 Lazarides, E., and Lindberg, U., Proc. Natl. Acad. Sci. USA 71 (1974) 4742 Liao, T.H., J. Formos. Med. Assoc. 96 (1997) 481-487 Liao, T.H., Mol. Cell Biochem. 34 (1981) 15-22 Nefsky, B., and Bretscher, A., Eur. J. Biochem. 179 (1989) 215-219 Nishikawa, A., and Mizuno, S., Biochem. J 355 (2001) 245-248 Nishikawa, A., et al., J. Biol. Chem. 272 (1997) 19408-19412 Paudel, H.K., and Liao, T.H., J. Biol Chem. 261 (1986) 16006-16011 Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001 Shak, S., Proc. Natl. Acad. Sci. USA 87 (1990) 9188-9192 Southern, P.J., and Berg, P., J. Mol. Appl. Genet. 1 (1982) 327-341 Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490 US 4,683,293 US 4,808,537 US 4,812,405 US 4,818,700 US 4,837,148 US 4,855,231 US 4,857,467 US 4,870,008 US 4,879,231 US 4,882,279 US 4,885,242 US 4,895,800 US 4,929,555 US 5,002,876 US 5,004,688 US 5,032,516 US 5,122,465 US 5,135,868 US 5,166,329 US 5,324,639 US 5,618,676 US 5,854,018 US 5,856,123 US 5,919,651 van Treeck, U., et al., Antimicrob Agents Chemother. 19 (1981) 371-380 Vedvick, T., et al., J. Ind. Microbiol. 7 (1991) 197-201 Waters et al., J. Biol. Chem. 263 (1988) 6209-14 Werten, M.W., et al., Yeast 15 (1999) 1087-1096 Worrall, A.F., and Connolly, B.A., J. Biol. Chem. 265 (1990) 21889-21895 38a SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: F. HOFFMANN-LA ROCHE AG
(ii) TITLE OF INVENTION: Recombinant bovine pancreatic Desoxyribunoclease I
with high specific activity (iii) NUMBER OF SEQUENCES: 29 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESS: OGILVY RENAULT
(B) STREET: 1981 MCGILL COLLEGE AVENUE, SUITE 1600 (C) CITY: MONTREAL
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) ZIP: H3A 2Y3 FILE REFERENCE: 3580-928CA
(v) COMPUTER READABLE FORM:
(D) SOFTWARE: Patentln Ver. 2.1 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,453,948 (B) FILING DATE: 2003-12-18 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: EP 02 028 115.0 (B) FILING DATE: 2002-12-18 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: EP 03 001 213.2 (B) FILING DATE: 2003-01-20 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/439,335 (B) FILING DATE: 2003-01-10 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 260 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO: L:
Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Her Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr 38b Asp Ile Val Leu Ile Gln Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gin Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Met Arg Gly Thr Arg Leu Met Gly Leu Leu Leu Ala Leu Ala Gly Leu Leu Gln Leu Gly Leu Ser Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gin Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn 38c Ser Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser 130. 135 140 Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp She Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro She Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 286 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO:
Met Arg Gly Thr Arg Leu Met Gly Leu Leu Leu Ala Leu Ala Gly Leu Leu Gln Leu Gly Leu Ser Leu Glu Lys Arg Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gin Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser Tyr Lys Glu Arg Tyr Leu She Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu She Ala Ile Val Ala Leu His 38d Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp She Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 345 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Bovine pancreatic DNase I; modified bovine pre-protein, i.e. with Saccharomyces cerevisiae a-factor signal peptide sequence and an signal peptidase cleavage site (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4::
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu She Ala Ala Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp She Asp Val Ala Val Leu Pro She Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser Leu Glu Lys Arg Leu Lys Ile Ala Ala She Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gln Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser 38e Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 783 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence: Nucleotide sequence encoding secreted bovine pancreatic DNase I, i.e. the protein without signal peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
ttgaagattg ctgctttcaa cattagaact ttcggtgaaa ctaaaatgtc taacgctact 60 ttggcatctt acatcgttag aattgtcaga agatatgata tcgttttaat tcaagaagtt 120 agagactctc acttggttgc agttggtaaa ttgttagact acttgaacca agatgaccca 180 aacacttacc actacgttgt ttctgaacca ttgggtagaa actcttacaa agaaagatac 240 ttattcttgt tcagaccaaa caaagtttca gttttggata cttaccaata cgacgacggt 300 tgcgaatctt gtggtaacga ttctttctcc agagaacctg ctgttgttaa attctcatca 360 cactctacca aggttaaaga gttcgctatc gttgctttgc attctgctcc ttctgacgct 420 gttgctgaaa ttaactcttt gtacgacgtt tacttagatg ttcaacagaa atggcacttg 480 aacgacgtca tgttgatggg tgactttaac gctgattgct cttatgttac ttcttctcaa 540 tggtcttcaa ttagattgag aacatcttca actttccaat ggttaattcc tgattccgct 600 gataccactg ctactagtac caactgtgct tacgatagaa tcgttgttgc tggatcatta 660 ttgcaatctt ctgttgtccc aggttcagcg gcccctttcg atttccaagc tgcatatggt 720 ttgtctaatg aaatggcttt agccatttct gatcactacc cagttgaagt cacattgaca 780 taa 783 38f (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Nucleotide sequence encoding the native bovine signal peptide sequence of the DNase I pre-protein nucleic acid sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
atgagaggta ctagattgat gggtttgtta ttagctttgg ctggtttatt acaattaggt 60 ttgtct 66 (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Nucleotide sequence encoding the native bovine signal peptide sequence of the DNase I pre-protein and an additional signal peptidase cleavage site (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
atgagaggta ctagattgat gggtttgtta ttagctttgg ctggtttatt acaattaggt 60 ttgtctctcg agaagaga 78 (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 255 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Saccharomyces cerevi:siae (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
atgagatttc cttcaatttt tactgctgtt ttattcgcag catcctccgc attagctgct 60 38g ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt 120 tactcagatt tagaagggga tttcgatgtt gctgttttgc cattttccaa cagcacaaat 180 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240 tctctcgaga agaga 255 (2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
gcgcctcgag aagagattga agattgctgc tttcaacatt agaactttcg gtgaaactaa 60 aatgtctaac gc 72 (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
cgatatcata tcttctgaca attctaacga tgtaagatgc caaagtagcg ttagacattt 60 tagattc 67 (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
gtcagaagat atgatatcgt tttaattcaa gaagttagag actctcactt ggttgcagtt 60 ggtaaattg 69 I
38h (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
cgtagtggta agtgtttggg tcatcttggt tcaagtagtc taacaattta ccaactgcaa 60 cc 62 (2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
ccaaacactt accactacgt tgtttctgaa ccattgggta gaaactctta caaagaaaga 60 tacttattct tg 72 (2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
ccaaacactt accactacgt tgtttctgaa ccattgggta gaaactctta caaagaaaga 60 tacttattct tg 72 38i (2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
ggatacttac caatacgacg acggttgcga atcttgtggt aacgattctt tctccagaga 60 acc 63 (2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
cgaactcttt aaccttggta gagtgtgatg agaatttaac aacagcaggt tctctggaga 60 aagaatcg 68 (2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
ccaaggttaa agagttcgct atcgttgctt tgcattctgc tccttctgac gctgttgc 58 38j (2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
gccatttctg ttgaacatct aagtaaacgt cgtacaaaga gttaatttca gcaacagcgt 60 cagaagg 67 (2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: :.9:
gatgttcaac agaaatggca cttgaacgac gtcatgttga tgggtgactt taacgctgat 60 tg 62 (2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
gttctcaatc taattgaaga ccattgagaa gaagtaacat aagagcaatc agcgttaaag 60 tcacc 65 38k (2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Descriptions of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
gtcttcaatt agattgagaa catcttcaac tttccaatgg ttaattcctg attccgctga 60 tacc 64 (2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
agcaacaacg attctatcgt aagcacagtt ggtactagta gcagtggtat cagcggaatc 60 agg 63 (2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
cgatagaatc gttgttgctg gatcattatt gcaatcttct ;ttgtcccag gttcagcggc 60 cc 62 (2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
ggctaaagcc atttcattag acaaaccata tgcagcttgg aaatcgaaag gggccgctga 60 acctgg 66 (2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
ctaatgaaat ggctttagcc atttctgatc actacccagt tgaagtcaca ttga 54 (2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
cgcgtctaga gcggccgctt atgtcaatgt gacttcaact gg 42 38m (2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
cgaaaaatga gaggtactag attgatgggt ttgttattag ctttggctgg tttattacaa 60 ttaggtttgt ctc 73 (2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
tcgagagaca aacctaattg taataaacca gccaaagcta ataacaaacc catcaatcta 60 gtacctctca ttttt 75 (2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 938 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Pichia pastoris (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 38n cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaa 938
Biochem. 179 (1989) 215-219. The purification process under the conditions of a research laboratory yields a specific activitiy in the range of 1,000 units per mg of protein obtained from 400 g of tissue, as explicitly reported by Paudel, H.K., and Liao, T.H., J. Biol Chem.
261 (1986) 16006-16011. In an upscaled industrial process, the isolation of bovine pancreatic desoxyribonuclease I from bovine pancreatic tissue yields preparations of isolated enzyme which usually exhibit a specific activity of 3,500 units per mg of protein (our own unpublished observation). Commercial preparations of research-grade bovine pancreatic desoxyribonuclease I purified from bovine pancreas usually have a specific activity below this value as exemplified by Roche products (Roche Diagnostics GmbH, Mannheim, Germany; catalogue items as of November 2002) having the catalogue numbers 1284932 (2,000 units/mg), 104132 (3,000 units/mg), 104159 (2,000 units/mg), and Sigma-Aldrich products (Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany;
catalogue items as of November 2002) having the catalogue numbers D5025 (2,000 units/mg) D4263 (2,000 U/mg), D4513 (2,000 units/mg), DN-25 (400-800 units/mg).
Generally, pancreas tissue as source for bovine pancreatic desoxyribonuclease I poses a problem as this tissue has a high content of other digestive pro-enzymes and their activated forms. On the one hand, the mixture from which the desired enzyme is purified is therefore very complex and requires elaborate separation techniques. On the other hand, proteases among the digestive enzymes may destroy the desired protein, especially during the first steps of the purification process when pancreatic tissue is homogenised. One could also speculate that pancreatic tissue homogenate contains inhibitory substances that inactivate a substantial portion of the bovine pancreatic desoxyribonuclease I, thereby limiting the specific activity of active enzyme that can be purified from this source.
It is also known to the art that recombinant expression of an enzymatically active bovine pancreatic desoxyribonuclease I protein in a bacterial host is possible.
However, overexpression poses a problem owing to the intrinsic toxicity of an endonuclease for a bacterial cell. Apparently, toxicity is caused by intracellular degradation of host cell DNA
with high levels of active bovine pancreatic desoxyribonuclease I enzyme being present in the bacterial cytoplasm. In a bacterial cell transcription and translation are tightly connected as opposed to eukaryotic cells where these processes take place in separate compartments, i.e. the nucleus and the cytoplasm. Thus, the selection of bacterial clones overexpressing bovine pancreatic desoxyribonuclease I at the same time promotes instability of these clones (e.g. genetic instability) and/or the recombinant desoxyribonuclease protein to be produced. Attempts to overcome this problem were mainly based on tightly regulated and inducible bacterial expression systems.
Worrall, A.F., and Connolly, B.A. (J. Biol. Chem. 265 (1990) 21889-21895) expressed an active bovine pancreatic desoxyribonuclease I protein in E. coli making use of a synthetic coding sequence adapted to the codon usage of the host organism.
Transcriptional expression was under the control of the XpL promoter. The recombinant protein was produced intracellularly and afterwards solubilised by means of sonication.
The recombinant active protein was found to be toxic for the bacterial host stain.
Thus, expression yield was in the range between 100 g to 1 mg/i culture. The specific activity of the recombinant active bovine pancreatic desoxyribonuclease I from E. coli was found to be identical to that of the native protein. The value given in the document (5x108 units/g of protein) was not the true value of the preparation but was corrected for purity. The recombinant bovine pancreatic desoxyribonuclease I protein was purified only partially and the document is completely silent about the specific desoxyribonuclease activity of a substantially pure and/or research-grade product.
Chen, C.Y., et al. (Gene 206 (1998) 181-184) expressed in E. coli a cDNA
representing the original bovine pancreatic transcript.: The construct was expressed in the strain BL21(DE3)pLysE and transcribed by an IPTG-inducible T7 polymerase. However, overexpression of an active bovine pancreatic desoxyribonuclease I was found to be limited in quantity and the product appeared to be toxic for the bacterial host organism. Due to cell lysis upon induction, bovine pancreatic desoxyribonuclease I activity was found in, the supernatant but also in the cellular fraction of the culture.
desoxyribonuclease enzyme activity was measured using an assay for enzyme activity that differed from the Kunitz assay in that there are changes with respect to divalent cations and their.
concentration in the reaction buffer, as well as its pH. However, generally the units detected by this assay appear to be comparable to those of the Kunitz assay. According to the assay of this document, the approximate yield from the induced culture was 3,500 units/l. The specific enzyme activity of the recombinant bovine pancreatic desoxyribonuclease I produced in E. coli was 908 units/mg was in the same range as the specific activity of native bovine pancreatic desoxyribonuclease I purified in parallel from pancreatic tissue (938 units/mg).
As it is commonly observed when post-translationally processed proteins of eukaryotic origin are expressed in a prokaryotic host system, the bovine pancreatic desoxyribonuclease I obtained by means of recombinant expression in E. coli markedly differs from the native protein. Particularly N-glycosylation which is a hallmark of the native pancreatic desoxyribonuclease I protein is absent in the recombinant product derived from prokaryotic expression systems. Glycosylation does not take place in E. coli and the publications by Worrall, A.F., and Connolly, B.A., J. Biol. Chem. 265 (1990) 21889-21895 as well as Chen, C.Y., et al., Gene 206 _ (1998) 181-184, confirm that the recombinantly produced bovine pancreatic desoxyribonuclease I proteins were not glycosylated. Also, folding of the protein and the formation of disulfide bonds are controlled differently in eukaryotic cells (Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing). Above all, the formation of disulfide bridges in the recombinantly produced protein can be assumed to occur randomly once SH groups of the protein come in contact with aerial oxygen.
Glycosylated bovine pancreatic desoxyribonuclease I also was expressed in cultured mammalian cells. Nishikawa, A., et al. (J. Biol. Chem. 272 (1997) 19408-19412) produced bovine pancreatic desoxyribonuclease I as well as human desoxyribonuclease I
in COS-1 cells in order to study mannose phosphorylation of these proteins. The document is however completely silent regarding yield or activity of the recombinant desoxyribonuclease I produced. A further glycosylation study on bovine pancreatic desoxyribonuclease I was published by Nishikawa, A., and Mizuno, S., Biochem.
J. 355 (2001) 245-248, dealing with the efficiency of N-linked glycosylation of bovine pancreatic desoxyribonuclease I. Also this document is completely silent regarding yield or activity of the recombinant desoxyribonuclease I produced.
Recombinant expression of human pancreatic desoxyribonuclease I in embryonic kidney 293 cells was described by Shak, S., Proc. Natl. Acad. Sci. USA 87 (1990) 9188-9192 as well as by the same author in WO 90/07572. In the latter document it is stated that the specific activity of recombinant human pancreatic desoxyribonuclease from 293 cells appeared to be comparable to that of bovine desoxyribonuclease (Sigma, product D5025) which was used as a reference. According to the supplier's (Sigma) catalogue the product has a specific activity of 2,000 units/mg which puts the recombinantly expressed human pancreatic desoxyribonuclease I protein in the same range. Moreover, according to the invention described in WO 90/07572, recombinant desoxyribonuclease is preferably expressed in mammalian cells but also in prokaryotes, fungi, yeast, pichia, insects and the like. However, apart from expression in mammalian cells the document does not disclose any other example for eukaryotic expression systems. Moreover, the document is completely silent regarding glycosylation, the formation of disulfide bridges and the specific activity of recombinant desoxyribonuclease when produced in other eukaryotic expression systems.
Furthermore, the document is completely silent on the impact of secretion on the yield of the desired protein as well as on its activity.
Using a similar expression system as in WO 90/07572, WO 96/26278 describes the production of human desoxyribonuclease I variants that exhibit a reduced binding affinity to actin. EP 1 122 306 discloses the expression of a human desoxyribonuclease II in HeLa cells.
The methods that are provided by the state of the art to produce a bovine pancreatic protein with desoxyribonuclease activity have certain disadvantages. The present invention provides an improved method.
It is an object of the invention to provide a cost-effective alternative source for bovine pancreatic desoxyribonuclease I. It is a further object of the invention to purify bovine pancreatic desoxyribonuclease I as a recombinant protein synthesised by a non-animal host organism. It is another object of the invention to provide an expression system in which the host organism tolerates the recombinant bovine pancreatic desoxyribonuclease I
better than bacteria. Another object of the invention is to provide an expression system which simplifies and accelerates the separation of bovine pancreatic desoxyribonuclease I from cellular or media components, therefore conserving enzyme activity which otherwise may be lost. Yet another object of the invention is to provide a production procedure that leads to an enzyme preparation with a high specific activity. Yet another object of the invention is that the production procedure is amenable to upscaling towards a cost-effective industrial process.
Brief summary of the invention It was surprisingly found that in case bovine pancreatic desoxyribonuclease I
is recombinatly expressed in the form of a pre-protein in methylotrophic yeast, whereby the methylotrophic yeast secretes the mature protein, the purified protein has an exceptionally high specific activity, that is to say a specific activity equal or higher than 6,000 units per mg of protein.
Thus, according to the invention, there is provided a method to produce a bovine pancreatic protein with desoxyribonuclease activity, comprising the steps of (a) providing a _9_ vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and' whereby the bovine pancreatic protein purified in step (d) is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein.
Therefore, the product is defined as a bovine pancreatic protein, obtainable by the method comprising the steps of (a) providing a vector comprising. a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and whereby the bovine pancreatic protein is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein Detailed description of the invention The enzyme bovine pancreatic desoxyribonuclease I is produced using methylotrophic yeast as a non-animal host organism. Methylotrophic yeasts have the biochemical pathways necessary for methanol utilization and are classified into four genera, based upon cell morphology and growth characteristics: Hansenula, Pichia, Candida, and Torulopsis. The most highly developed methylotrophic host systems utilize Pichia pastoris (Komagataella pastoris) and Hansenula polymorpha (Pichia angusta).
Expression of heterologous proteins in yeast is described in US 5,618,676, US
5,854,018, US 5,856,123, and US 5,919,651.
Yeast organisms produce a number of proteins that are synthesized intracellularly but have a function outside the cell. These extracellular proteins are referred to as secreted proteins.
Initially, the secreted proteins are expressed inside the cell in the form of a precursor or a pre-protein containing an N-terminal signal peptide ensuring effective direction of the expressed product into the secretory pathway of the cell, across the membrane of the endoplasmic reticulum. The signal peptide is generally cleaved off from the desired product during translocation. Cleavage is effected proteolytically by a signal peptidase. A particular sub-sequence of amino acids of the signal peptide is recognised and leaved by the signal peptidase. This sub-sequence is referred to as signal peptidase cleavage site.
Once having entered the secretory pathway, the protein is transported to the Golgi apparatus. From the Golgi apparatus the proteins are distributed to the plasma membrane, lysosomes and secretory vesicles.
Secreted proteins are confronted with different environmental conditions as opposed to intracellular proteins. Part of the processes of the secretory pathway is to stabilise the maturing extracellular proteins. Therefore, pre-proteins that are passed through the secretory pathway of yeast undergo specific posttranslational processing. For example, processing can comprise the generation of disulfide bonds to form intramolecular cross-links. Moreover, certain amino acids of the protein can be glycosylated.
Several approaches have been suggested for the expression and secretion in yeast of proteins heterologous to yeast. EP 0 116 201 describes a process by which proteins heterologous to yeast are transformed by an expression vector harboring DNA
encoding the desired protein, a signal peptide and a peptide acting as a signal peptidase cleavage site.
A culture of the transformed organism is prepared and grown, and the protein is recovered from culture media. For use in yeast cells a suitable signal peptide has been found to be the a-factor signal peptide from Saccharomyces cerevisiae (US 4,870,008).
When the present invention was made it was found surprisingly that the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein is also sufficient to direct the pre-protein to the secretory pathway of methylotrophic yeast.
Therefore, the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein can be used to express and secrete a heterologous gene product in methylotrophic yeast.
During secretion, the yeast enzyme KEX-2 is the signal peptidase which recognizes a Lysine-Arginine sequence as its cleavage site in the pre-protein. KEX-2 cleaves at the junction to the. sequence of the desired protein. As a result, the desired gene product is released and free of the leader portions, i.e. the signal peptide of the pre-protein. KEX-2 endoprotease was originally characterised in Saccharomyces yeast where it specifically processes the precursor of mating type a-factor and a killer factor (Julius, D., et al., Cell 37 (1984) 1075-1089). Methylotrophic yeast species such as Pichia pastoris share the KEX-2-type protease (similar role and function) with Saccharomyces cerevisiae (Werten, M.W., et al., Yeast 15 (1999) 1087-1096).
A well-established methylotrophic yeast species exemplarily described as host for high-level recombinant protein expression is Pichia pastoris (US 4,683,293, US 4,808,537, US 4,812,405, US 4,818,700, US 4,837,148, US 4,855,231, US 4,857,467, US
4,879,231) US 4,882,279, US 4,885,242, US 4,895,800, US 4,929,555, US 5,002,876, US
5,004,688, US 5,032,516, US 5,122,465, US 5,135,868, US 5,166,329, WO 00/56903). In the absence of glucose, Pichia pastoris uses methanol as a carbon source which at the same time is a hallmark of a methylotrophic organism. The alcohol oxidase (AOX1) promoter given in SEQ ID NO: 29 controls expression of alcohol oxidase, which catalyses the first step in methanol metabolism. Typically, 30% of the total soluble protein in methanol-induced cells is alcohol oxidase. Several Pichia expression vectors carry the AOXI
promoter and use methanol to induce high-level expression of desired heterologous proteins.
Expression constructs also integrate into the Pichia pastoris genome, creating a transformed and genetically stable host.
Using an expression vector encoding a heterologous pre-protein comprising a signal peptide or a signal peptide with a signal peptidase cleavage site, and a desired protein, methylotrophic yeast strains such as Pichia pastoris strains can be manipulated in order to secrete the desired product into the growth medium from where the secreted protein can be purified. It may be advantageous to produce nucleotide sequences encoding the pre-protein possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the pre-protein occurs in a particular yeast expression host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding the pre-protein, without altering the encoded amino acid sequences, include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.
Using a vector comprising the nucleotide sequence encoding the pre-protein that is competent for expression, e.g. operably linked to a promoter or promoter element and to a terminator or terminator element, as well as to sequences required for efficient translation, the host organism is transformed with a vector and transformants are selected.
Transformants are then analysed with respect to the yield of recombinant protein secreted into the growth medium. Transformants secreting the highest quantities of enzymatically active recombinant protein are selected. Thus, transformants secreting active bovine pancreatic desoxyribonuclease I with the highest specific activity are selected.
On the one hand, expression yield is dependent on proper targeting of the desired product, e.g. to the secretory pathway by means of a signal peptide such as the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. On the other hand, expression yield can be increased by increasing the dosage of the gene encoding the desired product, i.e. the copy number of the expression construct in the host organism is amplified. One way to accomplish this is by multiple transformation of an expression vector encoding the desired product. Another way is to introduce the gene encoding the desired product into the host organism using a first and a second expression vector, whereby the second expression vector is based on a selectable marker which differs from the selectable marker used in the first expression vector. The second expression vector encoding the same desired product can even be introduced when the host organism already carries multiple copies of a first expression vector (US 5,324,639; Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490; Vedvick, T., et al., J. Ind.
Microbiol. 7 (1991) 197-201; Werten, M.W., et al., Yeast 15 (1999) 1087-1096).
Secretion of expressed bovine pancreatic desoxyribonuclease I into the growth medium directs the mature recombinant protein to the extracytoplasmic space from where it diffuses into growth media. Thus, methylotrophic yeast grown in liquid culture secretes bovine pancreatic desoxyribonuclease I into the liquid growth medium, i.e. the liquid culture medium. This allows a. very efficient separation of yeast biomass from the recombinant protein using, e.g. filtration techniques. As a result, bovine pancreatic desoxyribonuclease I purified from this source is very efficiently freed from other enzyme activities such as RNase or protease activities.
High specific enzymatic activity also depends on the structure of bovine pancreatic desoxyribonuclease I. In order to bring about correct structure of a eukaryotic protein, processes like protein folding, the formation of intramolecular disulfide bonds or glycosylation can be involved. It is known that methylotrophic yeast as a eukaryotic host organism for recombinant expression is capable of glycosylating heterologous proteins. It is presumed that recombinant bovine pancreatic desoxyribonuclease I secreted by methylotrophic yeast is glycosylated. Furthermore it might well be possible that in addition disulfide bonds are formed in the course of the secretory pathway of the methylotrophic yeast.
It was surprisingly found that when bovine pancreatic desoxyribonuclease I is expressed and secreted by methylotrophic yeast into the growth medium, this leads to a pancreatic protein with desoxyribonuclease activity, whereby the specific desoxyribonuclease activity of the purified pancreatic protein is very high.
Thus, according to the invention, there is provided a method to produce a bovine pancreatic protein with desoxyribonuclease activity, comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, whereby the bovine pancreatic protein has desoxyribonuclease activity, and whereby the bovine pancreatic protein purified in step (d) is characterised by a specific desoxyribonuclease activity of at least 6,000 units per mg of protein.
Thus, there is provided a method to produce a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein purified in step (d), comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium.
The method therefore results in a purified bovine pancreatic protein that is bovine pancreatic desoxyribonuclease I, expressed as a heterologous pre-protein in a methylotrophic yeast strain and secreted as a mature protein into the growth medium.
Therefore, in a very preferred embodiment of the invention, the amino acid sequence of the bovine pancreatic protein is SEQ ID NO: 1, that is a nucleotide sequence comprising preferred codons of methylotrophic yeast.
Yeast-derived as well as non-yeast-derived eukaryotic signal peptides other than those particularly mentioned can be used for the same purpose. Although the signal peptides might not be cleavable by the signal peptidase, a signal peptidase cleavage peptide can be inserted into the pre-protein amino acid sequence, that is between the amino acid sequence of the signal peptide and the amino acid sequence of the bovine pancreatic desoxyribonuclease I polypeptide. Therefore, in yet another very preferred embodiment of the invention, the signal peptide contains a signal peptidase cleavage site which is located directly adjacent to the first amino acid of the bovine pancreatic protein.
Very preferred signal peptides are the signal peptides of the pre-proteins in SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. Therefore, in another very preferred embodiment of the invention, the amino acid sequence of the expressed pre-protein is selected from the group consisting of (a) SEQ ID NO: 2, (b) SEQ ID NO: 3, and (c) SEQ ID NO: 4. Thus, the vector encodes the amino acid sequences for bovine pancreatic desoxyribonuclease I
pre-proteins that enter the secretory pathway when expressed in methylotrophic yeast and particularly in Pichia pastoris.
Translation efficiency of a heterologous protein can be improved by adapting the codons of the nucleotide sequence encoding the heterologous protein according to the preferred codons in the host organism. In yet another very preferred embodiment of the invention, the nucleotide sequence encoding the bovine pancreatic protein is SEQ ID NO:
5. Thus, the nucleotide sequence in SEQ ID NO: 5 consists of codons that are preferred in methylotrophic yeast, particularly in Pichia, yet more particularly in Pichia pastoris.
In a preferred embodiment of the invention, the nucleotide sequence encoding the pre-protein consists of the nucleotide sequence encoding the signal peptide fused to the nucleotide sequence encoding the bovine pancreatic protein. In a very preferred embodiment of the invention, the nucleotide sequence encoding the signal peptide is selected from the group consisting of (a) SEQ ID NO: 6, (b) SEQ ID NO: 7, and (c) SEQ ID
NO: 8. SEQ ID NO: 6 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the native bovine pancreatic DNase I pre-protein. SEQ ID NO:
7 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the native bovine pancreatic DNase I pre-protein and an additional signal peptidase cleavage site. SEQ
ID NO: 8 is the nucleotide sequence encoding the amino acid sequence of the signal peptide of the a-factor from Saccharomyces cerevisiae. This signal .peptide is a bipartite signal peptide. Therefore, in yet another very preferred embodiment of the invention, the nucleotide sequence encodes a pre-protein selected from the group consisting of (a) SEQ
ID NO: 2, (b) SEQ ID NO: 3, and (c) SEQ ID NO: 4. Moreover, many sources of signal peptides are well known to those skilled in the art. In general, the nucleotide sequence encoding the pre-protein N-terminus of essentially any secreted protein is a potential preferred nucleotide sequence encoding the signal peptide of the bovine pancreatic desoxyribonuclease I pre-protein of the present invention.
In yet a further preferred embodiment of the invention, the nucleotide sequence encoding the pre-protein is operably linked to a promoter or promoter element.
It is also preferred that the promoter or the promoter element stimulates in the methylotrophic yeast strain transcription of the nucleotide sequence that encodes the pre-protein, to which the promoter or the promoter element is operably linked.
Very preferred is a promoter or promoter element from Pichia pastoris, even more preferred is the Pichia pastoris AOXl promoter given in SEQ ID NO: 29. It is also preferred that in addition the nucleotide sequence that encodes the pre-protein is operably linked with a terminator sequence that directs termination of transcription in the methylotrophic yeast strain. Very preferred is a terminator from Pichia pastoris, even more preferred is the Pichia pastoris AOX1 terminator.
In yet a further preferred embodiment of the invention, the vector is a plasmid capable of being replicated as an episome in the methylotrophic yeast strain. Thus, the preferred plasmid is a circular nucleic acid molecule that comprises an origin of replication directing replication of the episome in the methylotrophic yeast strain. Moreover, the plasmid comprises a selectable marker that is expressed in the methylotrophic yeast strain, whereby the selectable marker allows to select for the presence of the plasmid in the methylotrophic yeast strain. A very preferred selectable marker is a Zeocin"m resistance gene, that is the native form or a genetically engineered variant of the Sh ble gene from Streptoalloteichus hindustanus (Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009; Carmels, T., et al., Curr. Genet. 20 (1991) 309-314). Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418 (Southern, P.J., and Berg, P., J. Mol. Appl. Genet. 1 (1982) 327-341). An example for such a selectable marker is an aminoglycoside phosphotransferase gene.
In yet a further preferred embodiment of the invention, an artificial chromosome capable of being replicated in the methylotrophic yeast strain contains the vector.
Thus, the preferred artificial chromosome is a linear nucleic acid molecule that comprises at least one origin of replication, a centromere and terminal telomeres, thereby controlling replication, integrity and mitotic/meiotic distribution of the artificial chromosome in the methylotrophic yeast strain. Moreover, the vector that is contained in the artificial chromosome comprises a selectable marker that is expressed in the methylotrophic yeast strain and that allows to select for the presence of the vector in the artificial chromosome that is replicated in the methylotrophic yeast strain. A very preferred selectable marker is a Zeocin"' resistance gene, that is the native form or an artificial variant of the Sh ble gene from Streptoalloteichus hindustanus. Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418. An example for such a selectable marker is an aminoglycoside phosphotransferase gene.
In yet a further preferred embodiment of the invention, a chromosome of the methylotrophic yeast strain contains the vector. It is very preferred that the vector has a nucleotide sequence identical to a chromosomal sequence, thus allowing integration of the vector into the host chromosome by site-specific recombination. To this end, the Pichia pastoris AOX1 locus is even more preferred as a locus for integration the host chromosome by site-specific recombination. It is also very preferred that, the vector comprises a selectable marker that is expressed in the methylotrophic yeast strain and that allows to select for the presence of the vector in the methylotrophic yeast strain. A
very preferred selectable marker is a Zeocin' resistance gene, that is the native form or an artificial variant of the Sh ble gene from Streptoalloteichus hindustanus. Another very preferred selectable marker confers resistance against aminoglycoside antibiotics such as Hygromycin and G418. An example for such a selectable ' marker is an aminoglycoside phosphotransferase gene.
The person skilled in the art is aware of the fact that the yield of secreted bovine pancreatic protein obtainable from growth medium, such as liquid growth medium, can be increased when the number of copies of the nucleotide sequence encoding the pre-protein from which the bovine pancreatic protein is expressed and secreted is increased.
Thus, the yield of secreted bovine pancreatic protein obtainable from growth medium can be increased when number of copies of the vector in the genome of the methylotrophic yeast strain is increased. For example, the copy number of the vector can be increased by subjecting the methylotrophic yeast strain to repeated transformations of the vector and repeated selection rounds using increasing concentrations of the selective agent against which the selective marker comprised in the vector confers resistance (US 5,324,639;
Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490;
Vedvick, T., et al., J. Ind. Microbiol. 7 (1991) 197-201).
The person skilled in the art is also aware of the fact that repeated transformations can be carried out using more than one vector. For example, repeated transformations can be carried out using a first and a second vector, whereby the first and the second vector encode the same pre-protein, whereby in the first and in the second vector the nucleotide sequence encoding the pre-protein is operably linked to a promoter or promoter element, whereby the same bovine pancreatic protein is expressed and secreted, and whereby the first and the second vector confer resistance to a first and a second selection marker.
An example for a first selective marker is the Sh ble gene, that is the ZeocinTM resistance gene (Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009; Carmels, T., et al., Curr.
Genet. 20 (1991) 309-314). The protein encoded by the Sh ble gene binds ZeocinTM
stoichiometrically and with a strong affinity. The binding of ZeocinTM
inhibits its toxic activity thereby selecting for transformants containing the Sh ble gene. It is known to a person skilled in the art that increasing the concentration of ZeocinTM as the selective agent in the medium selects for an increase in the number of copies of the vector expressing the Sh ble gene. It is therefore advantageous to use a vector with the Sh ble gene as a selectable marker to generate by repeated transformation multiple transformants of the methylotrophic yeast strain containing multiple copies of the vector. It is furthermore advantageous that transformations are repeated and selection for even more resistant transformants is repeated until for the transformed methylotrophic yeast strain no further increase of the level of resistance to ZeocinTM is obtained anymore or no further increase of the ZeocinTM concentration in the selection medium is possible anymore.
In case a first and a second vector are used, an example for a second selection marker is resistance against aminoglycoside antibiotics (Southern, P.J., and Berg, P., J. Mol. Appl.
Genet. 1 (1982) 327-341) such as G418. Thus, an exemplarily second vector expresses a resistance gene that confers resistance against G418. For example, there are several aminoglycoside phosphotransferases known to the art that confer resistance to aminoglycoside antibiotics (van Treeck, U., et al., Antimicrob Agents Chemother. 19 (1981) 371-380; Beck, E., et al., Gene 19 (1982) 327-336). The aminoglycoside phosphotransferase I (APH-I) enzyme has the ability to inactivate the antibiotic G418 and is an established selectable marker in yeast (Chen, X.J., and Fukuhara, H., Gene (1988) 181-192).
Thus, for the purpose of further increasing the dosage of the nucleotide sequence encoding the pre-protein from which the bovine pancreatic protein is expressed and secreted, the second vector is advantageously used for further rounds of transformation and selection, whereby in this case a preferred selective agent is G418 and whereby for transformation the methylotrophic yeast strain transformed with the first vector is used.
In yet a further preferred embodiment of the invention, the methylotrophic yeast strain is a Hansenula, Pichia, Candida or Torulopsis species. In a very preferred embodiment of the invention, the methylotrophic yeast strain is selected from the group consisting of Pichia pastoris, Hansenula polymorpha, Candida boidinii and Torulopsis glabrata.
Even more preferred Pichia pastoris strains are deposited at the American Type Culture Collection (ATCC) with the accession numbers 201178, 201949, 204162, 204163, 204164, 204165, 204414, 204415, 204416, 204417, 20864, 28485, 34614, 60372, 66390, 66391, 66392, 66393, 66394, 66395, 76273, 76274, and 90925.
Yet, an even more preferred methylotrophic yeast strain is the Pichia pastoris strain with the American Type Culture Collection accesssion number 76273 or a derivative thereof.
Even more preferred Hansenula polymorpha strains are deposited at the American Type Culture Collection with the accession numbers 14754, 200499, 200500, 200501, 200502, 200503, 200504, 200505, 200506, 200507, 200508, 200509, 200510, 200511, 200512) 200513, 200838, 200839, 201322, 204205, 22023, 26012, 34438, 36669, 38626, 44954, 44955, 46059, 48180, 58401, 62809, 64209, 66057, 76722, 76723, 76760, 90438, 96694, 96695, MYA-335, MYA-336, MYA-337, MYA-338, MYA-339, and MYA-340.
Even more preferred Candida boidinii strains are deposited at the American Type Culture Collection with the accession numbers 18810, 201209, 20432, 26175, 32195, 32929, 36351, 38256, 38257, 44637, 46498, 48180, 56294, 56507, 56897, 60364, 62807, 90439, 90441, 96315, and 96926.
Even more preferred Torulopsis "glabrata strains are deposited at the American Type Culture Collection with the accession numbers 15126, 15545, 2001, 22019, 26512, 28226, 28290, 32312, 32554, 32936, 34147, 34449, 36909, 38326, 4135, 46433, 48435, 58561, 66032, 750, and 90030.
A person skilled in the art is familiar with the purification of bovine pancreatic desoxyribonuclease I by means of chromatography (Funakoshi, A., et al., J.
Biochem.
(Tokyo) 88 (1980) 1113-1138; Paudel, H.K., and Liao, T.H., J. Biol Chem. 261 (1986) 16006-16011; Nefsky, B., and Bretscher, A., Eur. J. Biochem. 179 (1989) 215-219). It is _19-preferred, however, that bovine pancreatic desoxyribonuclease I which has been secreted by a transformed methylotrophic yeast strain into the growth medium is purified using ion exchange chromatography. Very preferred as a solid phase for ion exchange chromatography is a cation exchanger. In a preferred embodiment of the invention, Bovine pancreatic desoxyribonuclease I binds to the cation exchanger in the presence of a bivalent cation and acetate at low conductivity of the liquid phase, that is in a binding buffer of low conductivity. A preferred bivalent cation is Mg2+, Cat+, or Mn2+. Preferred for low conductivity is the range of 0.5 - 10 mS/cm. Very preferred for low conductivity is the range of 1- 5 mS/cm. Even more preferred for low conductivity is the range of 3 mS/cm. It is also preferred that the binding buffer comprises a protease inhibitor.
Furthermore, it is preferred that the binding buffer has an acidic pH. A
preferred pH is in the range between 4.5 and 6.9. Even more preferred is a pH of 5Ø Other proteins can be removed almost completely by washing the solid phase repeatedly with the binding buffer of low conductivity, whereby bovine pancreatic desoxyribonuclease I remains bound to the solid phase, that is the cation exchanger. In another preferred embodiment of the invention, elution of bovine pancreatic desoxyribonuclease I is accomplished using an elution buffer with high conductivity in the presence of a bivalent cation and acetate, whereby a small elution volume is advantageous. A preferred bivalent cation is Mgt , Ca2t, or Mn2t. Also preferred is a concentration of 0.3 M NaCl in the elution buffer. It is furthermore preferred that the elution buffer comprises a protease inhibitor.
Furthermore, it is preferred that the elution buffer has an acidic pH. A preferred pH is in the range between 4.5 and 6.9. Even more preferred is a pH of 5Ø Preferred for high conductivity. is the range of 10 - 60 mS/cm. Very preferred for high conductivity is the range of 20 - 50 mS/cm. Even more preferred for high conductivity is the range of 30 - 40 mS/cm. It is further preferred to repeat the washing of the solid phase with binding buffer, that is a buffer with low conductivity as described above, in order to achieve a purity higher than about 95% of the eluted bovine pancreatic desoxyribonuclease I. Purity is to be tested by means of SDS PAGE, whereby gels are stained using Coomassie Blue. Also very preferred is a further purification step consisting of affinity chromatography using heparin sepharose.
Using this further step, a person skilled in the art is able to achieve about 98% purity of bovine pancreatic desoxyribonuclease I, to be tested by means of SDS PAGE, whereby gels are stained using Coomassie Blue. The specific desoxyribonuclease activity of the affinity-purified bovine pancreatic protein is at least 6,000 units per mg of protein.
Yet another preferred embodiment of the invention is a Pichia pastoris strain with a chromosome that contains a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, operably linked with the Pichia pastoris AOX1 promoter according to SEQ ID NO: 29 or a promoter element thereof, whereby the nucleotide sequence that encodes the pre-protein is SEQ ID
NO: 7 or SEQ ID NO: 8, fused to SEQ ID NO:5.
Yet another preferred embodiment of the invention is a bovine pancreatic protein with a specific desoxyribonuclease I activity of at least 6,000 units per mg of protein, obtainable by the method comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein consisting of the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic *yeast strain in a growth medium that contains nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium, whereby the bovine pancreatic protein is bovine pancreatic desoxyribonuclease I, and whereby the bovine pancreatic protein has desoxyribonuclease activity.
Another very preferred embodiment of the invention is a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein that retains at least 50% of its specific desoxyribonuclease activity after heat incubation at 75 C for 60 min, whereby during heat incubation the bovine pancreatic protein is dissolved in a storage buffer containing 20 mM TrisHCl, 2 mM MgC12: 4 mM CaC12i 50% glycerol; pH 7.6.
Yet another preferred embodiment of the invention is the use of a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein for hydrolysing DNA.
Yet another preferred embodiment of the invention is a kit of parts containing a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein and a reaction buffer comprising a divalent cation. Yet another very preferred embodiment of the invention is the kit of parts, whereby the bovine pancreatic protein is dissolved in a storage buffer containing water, glycerol, a protease inhibitor, and a divalent cation, whereby the reaction buffer contains a divalent cation contains selected from the group consisting of Mg2+, Ca2t and Mn2+.
The method of the present invention presents an alternative to the purification of bovine pancreatic desoxyribonuclease I. Furthermore, it allows the production and purification of an active bovine pancreatic desoxyribonuclease I enzyme with a very high specific activity.
The following examples, references, sequence listing and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
Description of the Figures Figure 1 Map of the plasmid pDNASE-1 which is a derivative of the commercially available plasmid pPICZaA (Invitrogen) that confers resistance to ZeocinTM. The insert denoted "DNAseI" is the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I protein (SEQ
ID NO: 5) that is fused to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae (SEQ ID NO: 8). "AOX1-Prom" denotes the Pichia pastoris AOXI promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Figure 2 Map of the plasmid pDNASE-2 which is a derivative of the commercially available plasmid pPIC9K (Invitrogen) that confers resistance to G418.
The insert denoted "DNAseI" is the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I protein (SEQ ID NO: 5) that is fused to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae (SEQ ID NO: 8). "AOXI-Prom denotes the Pichia pastoris AOX1 promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Figure 3 Map of the plasmid pDNASE-4 which is a derivative of the commercially available plasmid pPICZaA (Invitrogen) that confers resistance to ZeocinTM.. The insert denoted "Sig-DNAseI" is the fusion of the synthetic DNA sequence encoding the mature bovine secreted desoxyribonuclease I
protein (SEQ ID NO: 5) with the nucleotide sequence encoding the native bovine pancreatic' desoxyribonuclease I signal peptide sequence and an additional signal peptidase cleavage site (SEQ ID NO: 7). "AOX1-Prom" denotes the Pichia pastoris AOX1 promoter, "Term" denotes the .30 Pichia pastoris AOX1 terminator.
Figure 4 Map of the plasmid pDNASE-6 which is a derivative of the commercially available plasmid pPIC9K (Invitrogen) that confers resistance to G418.
The insert denoted "Sig-DNAseI" is the fusion of the synthetic DNA
sequence encoding the mature bovine secreted desoxyribonuclease I
protein (SEQ ID NO: 5) with the nucleotide sequence encoding the native bovine pancreatic desoxyribonuclease I signal peptide sequence and an additional signal peptidase cleavage site (SEQ ID NO: 7). "AOXI-Prom" denotes the Pichia pastoris AOX1 promoter, "Term" denotes the Pichia pastoris AOX1 terminator.
Exam lpeI
Synthesis of a yeast-adapted nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I protein Generally, standard methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL
Press, 2001.
In order to optimise each codon for the use in yeast, the encoding vector was synthesised de novo. The sequence of the mature bovine pancreatic desoxyribonuclease I
protein is given in SEQ ID NO: 1 and consists of 260 amino acids. Back-translation resulted in a nucleotide sequence of 783 base pairs including a stop codon. The yeast-adapted coding sequence is given in SEQ ID NO: 5. The coding sequence was divided into 18 DNA
oligonucleotides having a length of between 42 and 72 nucleotides. The single-stranded DNA
oligonucleotides were designed as a series of alternating coding strand and non-coding strand fragments, having complementary 5' and 3' overlaps with the neighbouring fragments. The DNA oligonucleotides used in this manner are given in SEQ ID
NO: 9, SEQ
ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID
NO:
15, SEQ ID NO. 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26. The overlapping region was chosen such that unspecific binding during an annealing reaction was largely suppressed. The DNA oligonucleotides representing the 5' end and 3' end of the sequence encoding SEQ ID NO: 1 included restriction endonuclease cleavage sites located upstream and downstream of the coding sequence, in order to facilitate insertion of the artificial nucleotide sequence into expression vectors. Upstream the 5' end of the sequence encoding SEQ ID NO: 1, an Xho I cleavage site and the codons for two amino acids of the C-terminus of the c -factor signal peptide from Saccharomyces cerevisiae were added. Downstream of the stop codon, i.e. the 3' end of the sequence encoding SEQ ID NO: 1, Not I and Bgl II cleavage sites were added.
Three larger DNA fragments were synthesised separately from DNA
oligonucleotides by means of the polymerise chain reaction (PCR). The first reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID
NO: 12, SEQ ID NO: 13, and SEQ ID NO: 14. The second reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID
NO:
18, SEQ ID NO: 19, and SEQ ID NO: 20. The third reaction comprised the DNA
oligonucleotides given in SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID
NO:
24, SEQ ID NO: 25, and SEQ ID NO: 26. In the course of PCR, in each cycle overlapping termini were annealed and complementary DNA strands were synthesised.
Therefore, the DNA oligonucleotides were enlarged stepwise until the final length of the fragment was reached. To this end, the annealing temperature was chosen according to the requirements of the overlapping regions, i.e. the region with the lowest melting temperature determined the annealing temperature. During subsequent cycles, the final fragment was amplified.
By means of agarose gel electrophoresis the three larger DNA fragments were separated from any by-products. Gel bands corresponding to the desired fragments were excised and DNA was isolated from agarose blocks using the "QlAquick Gel Extraction Kit"
(Qiagen catalogue no. 28704). The three larger DNA fragments were then combined in a further PCR in the same fashion as described above, in order to synthesise the complete vector encoding the mature bovine pancreatic desoxyribonuclease I protein. The first five PCR
cycles were made with the three larger DNA fragments without any further primers added.
Again, the annealing temperature was chosen according to the requirements of the overlapping regions, i.e. the region with the lowest melting temperature.
Subsequently, two DNA oligonucleotides representing the termini of the complete artificial nucleotide sequence were added. The annealing temperature was raised according to the requirements of the added primers, i.e. the primer with the lowest melting temperature determines the annealing temperature. The complete artificial nucleotide sequence was amplified in the course of 25 PCR cycles.
The complete DNA fragment encoding the mature bovine pancreatic desoxyribonuclease I
protein was subsequently inserted into a cloning vector and propagated in E.
coli using conventional techniques (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001). The nucleotide sequence of the complete DNA
fragment was verified by sequencing.
n. e ' Cloning of the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
In order to provide a nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein, two complementary single-stranded DNA oligonucleotides were synthesised. As in Example 1, the codons were designed according to the preferred codon usage in methylotrophic yeast. The DNA
oligonucleotides used are given in SEQ ID NO: 27, SEQ ID NO: 28. The 5' ends of the DNA
oligonucleotides were designed such that the annealed, i.e. double-stranded nucleic acid would have, terminal overhangs identical to the overhangs which would have been created by cleavage of restriction endonucleases Sfu I and Xho I. The orientation of the overhangs is given with respect to the coding strand with the Sfu I site being located at its 5' end and the Xho I site being located at its 3' end. Upstream of the coding sequence an optimal Kosak-sequence has been inserted, to facilitate efficient initiation of translation in the host organism.
Of each of the two DNA oligonucleotides 5 pg were dissolved in 10 mM TrisHCl pH 7.5, 10 mM MgC12, 50 mM NaCl, 1 mM Dithiothreitol and heated at 100 C for 5 minutes, so that unwanted secondary structures and irregular hybridisation products were broken up.
Subsequently, hybridisation was allowed to take place by slowly cooling the mixture to room temperature. The double-stranded nucleic acid was analysed in an agarose gel and directly used in a ligation reaction with the expression vector pPICZA
(Invitrogen, Carlsbad, CA, USA) which was linearised before with Sfu I and Xho 1. The resulting vector which carried the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was subsequently analysed by restriction enzyme digestion and agarose gel electrophoresis as well as by sequencing.
Ex,rple 3 Cloning of the artificial vector encoding mature bovine pancreatic desoxyribonuclease I in various expression vectors Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The artificial DNA fragment encoding the mature bovine pancreatic desoxyribonuclease I
that was generated from PCR fragments (see Example 1) was excised with Xho I
and Bgl II
(Roche Diagnostics GmbH). The fragment was isolated using the "QlAquick Gel Extraction Kit" according to the instructions of the manufacturer.
Case 1: The fragment was ligated into the pPICZA vector fusing the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I to the nucleotide sequence encoding the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I
pre-protein (see Example 2). Before the ligation reaction, the vector was similarly cleaved with Xho I and Bgl II, and isolated.
Case 2: The fragment was ligated into the pPICZaA vector fusing the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I to the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae. Before the ligation reaction, the vector was similarly cleaved with Xho I and Bgl II, and isolated.
The cloning procedure followed in Case 1 inserted a linker sequence - encoding Leucine-Glutamic acid-Lysine-Arginine into the reading frame between the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the sequence encoding the mature protein. The Leucine-Glutamic acid sequence was inserted by virtue of the Xho I site (CTCGAG). The Lysine-Arginine sequence is known to represent a KEX-2 signal peptidase cleavage site, needed to cleave off the signal peptide from the pre-protein in the course of the secretory pathway. The nucleotide sequence for the Lysine-Arginine sequence is comprised in SEQ ID NO: 7 that corresponds to the signal peptide amino acid sequence in SEQ ID NO: 3. The cloning procedure followed in Case 2 inserted the nucleotide sequence encoding the mature bovine pancreatic desoxyribonuclease I
directly and in-frame after the nucleotide sequence encoding the a-factor signal peptide from Saccharomyces cerevisiae.
In both cases, the nucleotide sequence encoding the recombinant pre-protein were under the control of the P. pastoris AOX-1 promoter (SEQ IN NO.: 29) which is inducible by methanol.
Construction was accomplished by joining in a total volume of 10 d 20 ng of linearised vector fragment (in a volume of 1 l), 100 ng of PCR fragment (in 3 1), and incubation overnight at 16 C in the presence of T4 DNA ligase (Roche Diagnostics GmbH) according to the instructions of the manufacturer. 5 p1 of the ligation preparation were subsequently used to transform competent (Hanahan, 1983) E. coli XLIBlue cells (Stratagene), in a total volume of 205 l. Following incubation on ice for 30 min, cells were heat-shocked at 42 C
for 90 sec. Subsequently, cells were transferred into 1 ml LB medium and incubated for 1 h at 37 C to allow for expression of selection- markers. Aliquots were plated afterwards on LB
plates containing 100 g/ml Zeocin and incubated for 15 h at 37 C. Resistant clones were picked, plasmids were isolated (Sambrook, Fritsch & Maniatis, Molecular Cloning, A
Laboratory Manual, 3rd edition, CSHL Press, 2001) and tested by means of restriction analysis as well as sequence analysis. Construct clones verified to be free of errors and cloning artifacts were selected. The expression vector harbouring bovine pancreatic desoxyribonuclease I with the a-factor signal peptide from Saccharomyces cerevisiae was designated pDNASE-1, the expression vector harbouring bovine pancreatic desoxyribonuclease I with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was designated pDNASE-4.
Example 4 Transformation of Pichia pastoris with pDNASE-1 and pDNASE-4 Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The host strains used were Pichia pastoris X-33, GS115, KM71H and SMD1168 (Invitrogen). Preferred strains were X-33 and KM71H. Transformation was aimed at stably integrating expression constructs into the genome of the host organism.
Initially, 5 ml YPD medium (YPD = yeast peptone dextrose; Invitrogen) was inoculated with a P. pastoris colony and pre-cultured on a shaker overnight at 30 C. To prepare transformation-competent cells, 100. l of the pre-culture were added as inoculum to 200 ml of fresh YPD medium and grown until an OD600nm of between 1.3 and 1.5 was reached. The cells were centrifuged at 1,500 x g for 5 min and resuspended in 200 ml ice cold (0 C) sterile water. The cells were centrifuged again at 1,500 x g for 5 min and resuspended in 100 ml ice cold sterile water. The cells were centrifuged one more time at 1,500 x g for 5 min and resuspended in 10 ml ice cold 1 M sorbitol (ICN). The cells prepared in this way were kept on ice and used for transformation immediately.
The expression vectors pDNASE-1 and pDNASE-4 to be used for transformation were linearised using the Sac I restriction endonuclease (Roche Diagnostics GmbH), precipitated and resuspended in water. Transformation was accomplished by eectroporation using a "Gene Pulser IITM" (BioRad). For. a transformation setting, 80 l P. pastoris cells in 1 M
sorbitol solution were mixed gently with 1 g of linearised expression vector DNA and transferred into an ice cold cuvette which was then kept on ice for 5 min.
Subsequently, the cuvette was transferred into the Gene Pulser. Electroporation parameters were 1 kV, 1 kQ
and 25 F. Following eectroporation, 1 ml 1 M sorbitol solution was added to the cell suspension was subsequently plated onto YPDS plates (YPDS = yeast peptone dextrose sorbitol; Invitrogen) containing 100 g/ml ZeocinTM (Invitrogen), with 100-150 l of cell suspension being spread on a single plate. YPDS plates were incubated at 30 C
for 2-4 days.
Yeast clones were transferred onto gridded minimal dextrose plates. Colonies from these plates were picked and separately resuspended in sterile water. The cells were digested with 17.5 units of lyticase (Roche Diagnostics GmbH) for 1 h at 30 C and afterwards frozen for 10 min at -80 C. By means of PCR, the presence of the expression cassettes of pDNASE-1 and pDNASE-4 was verified. The term "expression cassette" denotes a nucleotide sequence encoding the bovine pancreatic desoxyribonuclease I pre-protein, operably linked to the AOX1 promoter and the AOX1 terminator, whereby the expression cassette is derived from the respective pDNASE vector used for transformation. As for vectors containing an expression cassette, the terms "vector" and "expression vector" are synonyms.
Positive clones, i.e. clones that were tested positively for the presence of complete expression cassettes stably integrated into the genome were used for further characterisation of bovine pancreatic desoxyribonuclease I expression.
Additionally, control transformations were made with the recipient Pichia pastoris X33 strain using the pPICZaA vector. Positive clones were obtained and verified in a similar fashion.
Example 5 Expression and secretion of recombinant bovine pancreatic desoxyribonuclease I, analysis of pre-proteins with different signal peptides Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
A set of positive clones (usually 20-30) transformed with pDNASE-1 and pDNASE-4 (see Example 4) were grown as shaking cultures overnight, each in 3 ml BMGY medium.
(BMGY = buffered glycerol-complex medium; Invitrogen). Afterwards, the OD600nm values of the cultures were determined before they were passaged into shaking flasks, each containing 10 ml BMMY medium (Invitrogen) at pH 3. Pre-cultures were used as inoculum to result each in an OD600nm of 1. The cultures were kept on a shaker at 30 C. In parallel, positive control clones were cultured under the same conditions.
BMMY (BMMY = buffered methanol-complex medium;) medium comprises methanol.
(Mallinckrodt Baker B.V.) which is an inductor of the AOX-1 promoter that controls.
transcription of the recombinant bovine pancreatic desoxyribonuclease I
sequences inserted into the expression vectors.
Samples of 500 l were taken from the shaking flask in 24 h intervals over a total time of 72 h. When a sample aliquot was removed, the culture was also fed with 0.5%
methanol.
Samples of the supernatant growth medium were tested for desoxyribonuclease enzymatic activity.
Example 6 Analysis of expression of recombinant bovine pancreatic desoxyribonuclease I
Of the sample aliquots obtained as described in Example S firstly the OD600nn, was determined. Subsequently the cells were pelleted by centrifugation and the supernatant was saved. Desoxyribonuclease activity was measured in the undiluted supernatant as well as in a 1:10 dilution (Example 10).
While control clones transformed with the pPICZaA vector did not lead to any measurable desoxyribonuclease activity in the medium, Pichia strains transformed with both pDNASE-1 and pDNASE-4 showed desoxyribonuclease activity due to bovine pancreatic desoxyribonuclease I secreted into the growth medium, i.e. the culture medium.
It could therefore be concluded that that expression of a recombinant pre-protein comprising either the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein enables secretion of an active enzyme having desoxyribonuclease activity.
Regarding the yield of secreted mature protein, i.e. the desired bovine pancreatic desoxyribonuclease I, there were no obvious differences between the strains expressing the pre-protein with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein with the a-factor signal peptide from Saccharomyces cerevisiae.
Example 7 Increasing expression yield by multiple transformation and increased ZeocinTM
concentration Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
The yeast clones transformed with the expression vectors pDNASE-1- and pDNASE-4 that were found to produce the highest desoxyribonuclease activities in supernatant media were subjected to repeated electroporation using the same expression vector as previously.
Conditions for electroporation were as described in Example 4 with the exception that YPDS plates contained ZeocinT"' at increased concentrations, that is between 1,000 and 2,000 Vg/ml. The concentration of the antibiotic was increased in order to select for transformants having incorporated into their genome multiple copies of the respective expression vector. Yeast clones with increased resistance to the antibiotic were transferred onto gridded minimal dextrose plates. As already described in Example 5, pre-cultures were made from individual yeast clones and expression was measured by determining the desoxyribonuclease enzymatic activity secreted into the growth medium as described in Example 6. Individual clones were found that produced an increased amount of desoxyribonuclease activity. This was the case for yeast transformants expressing both types of recombinant pre-protein, i.e. pre-protein comprising either the a-factor signal peptide from Saccharomyces cerevisiae or the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein. On the average, desoxyribonuclease activity measured in the supernatant of Pichia strains repeatedly transformed with pDNASE-1- or pDNASE-4 was between twice to three times as high compared to the respective precursor strains that had undergone only a single transformation.
Regarding the yield of secreted mature protein, there were no obvious differences between the strains expressing the pre-protein with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein with the a-factor signal peptide from Saccharomyces cerevisiae.
Example 8 Increasing expression yield by means of introducing a different expression vector allowing to apply further selection pressure Generally, the methods suggested and described in the Invitrogen manuals "Pichia Expression Kit" Version M 011102 25-0043, "pPICZ A, B, and C" Version D 110801 0148, "pPICZa A, B, and C" Version E 010302 25-0150, and "pPIC9K" Version E
25-0106 were applied. Reference is also made to further vectors, yeast strains and media mentioned therein. Basic methods of molecular biology were applied as described in Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001.
From the expression vectors pDNASE-1 and pDNASE-4 the expression cassette consisting of a part of the AOX-1 promoter and the reading frame for the respective pre-protein (see Figures 1 and 3) was excised using restriction endonucleases Sac I and Xba I
(Roche Diagnostics GmbH). The resulting cleavage products were separated by agarose gel electrophoresis. In the case of pDNASE-1, a fragment having the size of 1765 bp was excised and isolated using the "QlAquick Gel Extraction Kit" (Qiagen). In the case of pDNASE-4, a fragment having the size of 1560 bp was excised and isolated using the "QIAquick Gel Extraction Kit"
(Qiagen). In both fragments, the Xba I overhang was converted to a blunt end using Klenow polymerase (Roche Diagnostics GmbH).
The vector pPIC9K (Invitrogen) was cleaved using restriction endonucleases Sac I and Not I (Roche Diagnostics GmbH). The resulting cleavage products were separated by agarose gel electrophoresis. A fragment with a size of 8956 bp was excised and isolated using the "QlAquick Gel Extraction Kit" (Qiagen). The Not I overhang was converted to a blunt end using Klenow polymerase (Roche Diagnostics GmbH). The expression cassettes prepared from pDNASE-1 and pDNASE-4 were inserted separately. Ligation, bacterial transformation and cloning procedures were performed as described in Example 3 with the exception that transformed bacterial clones were selected on LB plates containing 100 pg/ml of the antibiotic ampicillin. Clones were verified by means of restriction analysis and sequencing. The pPIC9K-derived expression vector harbouring bovine pancreatic desoxyribonuclease I with the a-factor signal peptide from Saccharomyces cerevisiae was designated pDNASE-2, the pPIC9K-derived expression vector harbouring bovine pancreatic desoxyribonuclease I with the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein was designated pDNASE-6.
Using the pPIC9K-derived expression vectors, resistance to the antibiotic G418 was introduced. Among the Pichia pastoris ZeocinTM-resistant transformants having incorporated into their genome multiple copies of the pDNASE-1 and pDNASE-4 expression vectors those were selected that secreted into the growth medium the highest amounts of desoxyribonuclease activity. Clones containing multiple copies of pDNASE-1 were transformed with pDNASE-2 and clones containing multiple copies of pDNASE-were transformed with pDNASE-6. Expression vectors to be used were linearised using the Sal I restriction endonuclease (Roche Diagnostics GmbH). 1 g of the respective linearised expression vector was used for transformation which was performed as described in Example 4. Following electroporation, the cells were kept at 4 C in 1 M
sorbitol for a period of between 1 and 3 days, in order to allow the cells become resistant to the antibiotic. The cell suspension was plated onto YPDS plates (Invitrogen) containing 1, 2 and 4 mg/ml G418 (Roche Diagnostics GmbH), with 100-200 l of cell suspension being spread on a single plate. YPDS plates were incubated at 30 C for 3-5 days.
Yeast clones were transferred onto gridded minimal dextrose plates. Clones originating from YPDS
plates with the highest G418 concentration were preferentially transferred. Selected clones were characterised further as described in Example 4.
Multiply transformed and verified Pichia clones carrying multiple copies of expression vectors conferring Zeocin"" resistance as well as the expression vector conferring resistance to G418 were characterised with respect to the amount of desoxyribonuclease activity secreted into the growth medium. Assays were performed as described in Example 5.
Clones harbouring pDNASE-1 and pDNASE-2 constructs were identified which produced an even higher level of secreted desoxyribonuclease enzymatic activity than the precursor clones containing only multiple copies of pDNASE-1 but, not pDNASE-2.
Additionally, clones harbouring pDNASE-4 and pDNASE-6 constructs were identified which produced an even higher level of secreted desoxyribonuclease enzymatic activity than the precursor clones containing only multiple copies of pDNASE-4 but not pDNASE-6. On the average, desoxyribonuclease activity measured in the supernatant of cultures that were transformed with pDNASE-2 or pDNASE-6, i.e. in addition to multiple transformations with pDNASE-1 or pDNASE-4, was found to be about four times as high when compared to the respective precursor strains that had undergone only a single transformation.
Regarding the yield of secreted mature protein, there were no obvious differences between the strains expressing the pre-protein comprising the bovine signal peptide of the native bovine pancreatic desoxyribonuclease I pre-protein and the pre-protein comprising the a-factor signal peptide from Saccharomyces cerevisiae.
Example 9 Purification of recombinant bovine pancreatic desoxyribonuclease I protein from liquid culture supernatant Biomass was removed from the supernatant growth medium by filtration or by centrifugation. Bovine pancreatic desoxyribonuclease I was subsequently purified by means of ion exchange chromatography using a cation exchanger. A cation exchanger that was used with success was SP sepharose. Bovine pancreatic desoxyribonuclease I was bound to the cation exchanger at low conductivity of the liquid phase, that is in a binding buffer of low conductivity. Low conductivity corresponded to a value of conductivity between 2 -3 mS/cm. The binding buffer had a pH of 5.0 and contained 20 mM Ca 2-' acetate and 1 mM PefablocT'". Other proteins were removed by washing the solid phase repeatedly with binding buffer, whereby the bovine pancreatic desoxyribonuclease I remained bound by the solid phase, that is the cation exchanger. Elution of bovine pancreatic desoxyribonuclease I was accomplished using an elution buffer with high conductivity.
High conductivity corresponded to a value of conductivity between 30 40 mS/cm.
The elution buffer had a pH of 5.0 and contained 0.3 M NaCl, 20 mM Ca 2+ acetate and 1 mM
Pefabloc'. The purity of the bovine pancreatic desoxyribonuclease I achieved after this step was higher than about 95% as tested by means of SDS PAGE, whereby gels were stained using Coomassie Blue. The subsequent purification step was affinity chromatography using heparin sepharose to remove RNase activity. The buffer system used was 2 mM Tris/HCJ pH 6.5 with a conductivity 2.1 +/- 0.1 mS/cm. The bovine pancreatic desoxyribonudease I not is bound to the solid phase. Following this step, the purity of the bovine pancreatic desoxyribonuclease I was higher than about 98%
as tested by means of SDS PAGE, whereby gels were stained using Coomassie Blue. The specific desoxyribonuclease activity of the affinity-purified bovine pancreatic desoxyribonuclease I
was higher than or equal to 6;000 units per mg of protein.
Example 10 Assay to determine the specific desoxyribonuclease activity of purified bovine pancreatic desoxyribonuclease I in growth culture supernatant The test for desoxyribonuclease activity in sample aliquots was performed according to Kunitz, M., J. Gen. Physiol. 33 (1950) 349-62 and 363. Calf thymus DNA was dissolved at a concentration of 0.05 mg/ml in a buffer containing 10 mM TrisHCl pH 8.0, 0.1 mM CaC12, 1 mM MgC12. Purified desoxyribonuclease activity-containing growth medium such as culture supernatant was added and the increase of the extinction at 260 nm was photometrically measured over time at 25 C. 1 unit (1 U) corresponds to an extinction increase (DE) of 0.001 per min. Representative results are given in Table 1.
Table 1 Determination of desoxyribonuclease activity in the culture supernatant of three different transformed strains of Pichia pastoris Strain 1 Strain 2 Strain 3 Assayed volume of culture supernatant 0.01 ml 0.007 ml 0.007 ml DE / min 0.0114 0.0133 0.0155 U / ml 1,425 2,375 2,065 Exam 1 Assay to determine the specific desoxyribonuclease activity of purified bovine pancreatic desoxyribonuclease I
The desoxyribonuclease-free reference sample was the sample buffer, that is a mixture of 1 part 1 M sodium acetate pH 5.0, 1 part 50 mM MgSO4 and 8 parts double-distilled water.
For the substrate buffer, calf thymus DNA was dissolved in a buffer containing 5 mM
MgSO4 and 100 mM sodium acetate pH 5.0 and incubated between 24 to 30.hours in a water bath at 37 C. Unsoluble parts were removed by centrifugation for 10 min at 13,000 x g. Substrate buffer contained DNA at a concentration of 0.04 mg/mi.
DNA
content of the supernatant was determined photometrically at 260 nm and, if necessary, the substrate buffer was adjusted with sample buffer to give an extinction value of 0.8.
Substrate buffer was stored for at least 3 days at 4 C before use.
DNase-containing solution with a volume activity of about 10,000 units per ml obtained from purification of bovine pancreatic desoxyribonuclease I according to Example 9 was used for the determination of desoxyribonuclease activity. 5 .d of the desoxyribonuclease-containing solution was diluted with 95 l double-distilled water. Firstly, 2.5 ml substrate buffer was filled into a quartz cuvette with a thickness of 1 cm. Both the substrate buffer and the cuvette were kept at 25 C, measurements were at the same temperature.
The wave length at which measurements were taken was 260 nm. After the photometer was set to zero extinction (reference value) 0.05 nil diluted desoxyribonuclease-containing solution was added and mixed. The increase of the extinction (AE/min) was measured over time.
One unit (1 U) corresponds to the activity that under the conditions as described above leads to an increase of the extinction of 0.001 per min.
The activity per volume given as was calculated as [U / ml] 2,55 x 1,000 x DE/min 0.05 The activity of undiluted bovine pancreatic desoxyribonuclease I preparations was calculated according to the dilution factor applied. It was also generally observed that the units measured using this assay were comparable to those of the Kunitz assay.
Additionally, protein content was measured using the same type of cuvettes as above.
Measurements were taken of purified bovine pancreatic desoxyribonuclease I in sample buffer at temperatures between 20 C and 25 C, at a wave length of 280 nm, with the sample buffer serving as reference.
The protein content was calculated from extinction values (AE280) as [mg protein / ml] = AE280 x 0.796 Each measurement was taken in triplicate. Specific desoxyribonuclease activity in a given volume was then calculated as units per mg of protein. Representative results are given in Table 2.
Table 2 Determination of specific desoxyribonuclease activity of bovine pancreatic desoxyribonuclease I purified from the culture supernatant of three different multiply transformed strains of Pichia pastoris Strain 1 Strain 2 Strain 3 Assayed volume of purified 0.01 ml 0.04 ml 0.04 ml desoxyribonuclease preparation iE / min 0.008 0.011 0.0105 U / ml 99,375 17,266 16,328 AE280 0.099 0.134 0.133 mg of protein / ml 15.8 2.13 2.1 specific desoxyribonuclease activity 6,289 8,106 7,775 Exarnple 12 Thermostability of purified active bovine pancreatic desoxyribonuclease I
Aliquots of purified bovine pancreatic desoxyribonuclease I in a storage buffer containing mM TrisHC1, 2 mM MgC12i 4 mM CaC12, 50% glycerol, pH 7.6 were incubated for 60 min at 55 C, 60 C, 65 C, 70 C, 75 C, and 80 C, whereby each aliquot had a volume of 500 l and contained at least 10,000 units per ml. Each aliquot was kept over the heating period in a fine-regulated (variation limit less than 0.5 C) thermostate block heater.
20 Immediately after the incubation, residual specific desoxyribonuclease activity was measured as activity per volume using the assay as described in 0.
Representative results are tabulated in Table 3. Residual activity per volume after heat treatment is given as a percentage with the activity of an untreated control aliquot being set as 100%. No differences regarding heat stability were found with respect to Pichia yeast strains used for transformation (see e.g. Example 4) or the kind of signal peptides present in the respective pre-protein (see e.g. Examples 3, 5, 6, 7, 8) Table 3 Residual specific desoxyribonuclease activity after heat incubation Temperature Residual specific 91% 86% 73% 58% 52% 46%
desoxyribonuclease activity after 60 min List of References Alberts,-B., Johnson, A., Lewis, J., Raff, M., Roberts, K., Walter, P. (eds), Molecular Biology of the Cell, fourth edition, 2002, Garland Science Publishing Beck, E., et al., Gene 19 (1982) 327-336 Carmels, T., etal., Curr. Genet. 20 (1991) 309-314 Chen, C.Y., et al., Gene 206 (1998) 181-184 Chen, X.J., and Fukuhara, H., Gene (1988) 181-192 Drocourt, D., et al., Nucleic Acids Res. 18 (1990) 4009 Funakoshi, A., et al., J. Biochem. (Tokyo) 88 (1980) 1113-1138 Julius, D., et al., Cell 37 (1984) 1075-1089 Kaighn, M.E., In: Tissue culture, methods and applications; Kruse, P. F. &
Patterson, M. K., eds., Academic Press, New York & London, 1973, 54-58 Kunitz, M., J. Gen. Physiol. 33 (1950) 349-62 and 363 Lazarides, E., and Lindberg, U., Proc. Natl. Acad. Sci. USA 71 (1974) 4742 Liao, T.H., J. Formos. Med. Assoc. 96 (1997) 481-487 Liao, T.H., Mol. Cell Biochem. 34 (1981) 15-22 Nefsky, B., and Bretscher, A., Eur. J. Biochem. 179 (1989) 215-219 Nishikawa, A., and Mizuno, S., Biochem. J 355 (2001) 245-248 Nishikawa, A., et al., J. Biol. Chem. 272 (1997) 19408-19412 Paudel, H.K., and Liao, T.H., J. Biol Chem. 261 (1986) 16006-16011 Sambrook, Fritsch & Maniatis, Molecular Cloning, A Laboratory Manual, 3rd edition, CSHL Press, 2001 Shak, S., Proc. Natl. Acad. Sci. USA 87 (1990) 9188-9192 Southern, P.J., and Berg, P., J. Mol. Appl. Genet. 1 (1982) 327-341 Thill, G.P., et al., Positive and Negative Effects of Multi-Copy Integrated Expression in Pichia pastoris, International Symposium on the Genentics of Microorganisms 2 (1990), pp. 477-490 US 4,683,293 US 4,808,537 US 4,812,405 US 4,818,700 US 4,837,148 US 4,855,231 US 4,857,467 US 4,870,008 US 4,879,231 US 4,882,279 US 4,885,242 US 4,895,800 US 4,929,555 US 5,002,876 US 5,004,688 US 5,032,516 US 5,122,465 US 5,135,868 US 5,166,329 US 5,324,639 US 5,618,676 US 5,854,018 US 5,856,123 US 5,919,651 van Treeck, U., et al., Antimicrob Agents Chemother. 19 (1981) 371-380 Vedvick, T., et al., J. Ind. Microbiol. 7 (1991) 197-201 Waters et al., J. Biol. Chem. 263 (1988) 6209-14 Werten, M.W., et al., Yeast 15 (1999) 1087-1096 Worrall, A.F., and Connolly, B.A., J. Biol. Chem. 265 (1990) 21889-21895 38a SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: F. HOFFMANN-LA ROCHE AG
(ii) TITLE OF INVENTION: Recombinant bovine pancreatic Desoxyribunoclease I
with high specific activity (iii) NUMBER OF SEQUENCES: 29 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESS: OGILVY RENAULT
(B) STREET: 1981 MCGILL COLLEGE AVENUE, SUITE 1600 (C) CITY: MONTREAL
(D) STATE: QUEBEC
(E) COUNTRY: CANADA
(F) ZIP: H3A 2Y3 FILE REFERENCE: 3580-928CA
(v) COMPUTER READABLE FORM:
(D) SOFTWARE: Patentln Ver. 2.1 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER: 2,453,948 (B) FILING DATE: 2003-12-18 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: EP 02 028 115.0 (B) FILING DATE: 2002-12-18 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: EP 03 001 213.2 (B) FILING DATE: 2003-01-20 (vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 60/439,335 (B) FILING DATE: 2003-01-10 (2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 260 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO: L:
Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Her Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr 38b Asp Ile Val Leu Ile Gln Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gin Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 282 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
Met Arg Gly Thr Arg Leu Met Gly Leu Leu Leu Ala Leu Ala Gly Leu Leu Gln Leu Gly Leu Ser Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gin Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn 38c Ser Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser 130. 135 140 Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp She Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro She Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 286 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Bos taurus (xi) SEQUENCE DESCRIPTION: SEQ ID NO:
Met Arg Gly Thr Arg Leu Met Gly Leu Leu Leu Ala Leu Ala Gly Leu Leu Gln Leu Gly Leu Ser Leu Glu Lys Arg Leu Lys Ile Ala Ala Phe Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gin Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser Tyr Lys Glu Arg Tyr Leu She Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu She Ala Ile Val Ala Leu His 38d Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp She Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 345 (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Bovine pancreatic DNase I; modified bovine pre-protein, i.e. with Saccharomyces cerevisiae a-factor signal peptide sequence and an signal peptidase cleavage site (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4::
Met Arg Phe Pro Ser Ile Phe Thr Ala Val Leu She Ala Ala Ser Ser Ala Leu Ala Ala Pro Val Asn Thr Thr Thr Glu Asp Glu Thr Ala Gln Ile Pro Ala Glu Ala Val Ile Gly Tyr Ser Asp Leu Glu Gly Asp She Asp Val Ala Val Leu Pro She Ser Asn Ser Thr Asn Asn Gly Leu Leu Phe Ile Asn Thr Thr Ile Ala Ser Ile Ala Ala Lys Glu Glu Gly Val Ser Leu Glu Lys Arg Leu Lys Ile Ala Ala She Asn Ile Arg Thr Phe Gly Glu Thr Lys Met Ser Asn Ala Thr Leu Ala Ser Tyr Ile Val Arg Ile Val Arg Arg Tyr Asp Ile Val Leu Ile Gln Glu Val Arg Asp Ser His Leu Val Ala Val Gly Lys Leu Leu Asp Tyr Leu Asn Gln Asp Asp Pro Asn Thr Tyr His Tyr Val Val Ser Glu Pro Leu Gly Arg Asn Ser 38e Tyr Lys Glu Arg Tyr Leu Phe Leu Phe Arg Pro Asn Lys Val Ser Val Leu Asp Thr Tyr Gln Tyr Asp Asp Gly Cys Glu Ser Cys Gly Asn Asp Ser Phe Ser Arg Glu Pro Ala Val Val Lys Phe Ser Ser His Ser Thr Lys Val Lys Glu Phe Ala Ile Val Ala Leu His Ser Ala Pro Ser Asp Ala Val Ala Glu Ile Asn Ser Leu Tyr Asp Val Tyr Leu Asp Val Gln Gln Lys Trp His Leu Asn Asp Val Met Leu Met Gly Asp Phe Asn Ala Asp Cys Ser Tyr Val Thr Ser Ser Gln Trp Ser Ser Ile Arg Leu Arg Thr Ser Ser Thr Phe Gln Trp Leu Ile Pro Asp Ser Ala Asp Thr Thr Ala Thr Ser Thr Asn Cys Ala Tyr Asp Arg Ile Val Val Ala Gly Ser Leu Leu Gln Ser Ser Val Val Pro Gly Ser Ala Ala Pro Phe Asp Phe Gln Ala Ala Tyr Gly Leu Ser Asn Glu Met Ala Leu Ala Ile Ser Asp His Tyr Pro Val Glu Val Thr Leu Thr (2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 783 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence: Nucleotide sequence encoding secreted bovine pancreatic DNase I, i.e. the protein without signal peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
ttgaagattg ctgctttcaa cattagaact ttcggtgaaa ctaaaatgtc taacgctact 60 ttggcatctt acatcgttag aattgtcaga agatatgata tcgttttaat tcaagaagtt 120 agagactctc acttggttgc agttggtaaa ttgttagact acttgaacca agatgaccca 180 aacacttacc actacgttgt ttctgaacca ttgggtagaa actcttacaa agaaagatac 240 ttattcttgt tcagaccaaa caaagtttca gttttggata cttaccaata cgacgacggt 300 tgcgaatctt gtggtaacga ttctttctcc agagaacctg ctgttgttaa attctcatca 360 cactctacca aggttaaaga gttcgctatc gttgctttgc attctgctcc ttctgacgct 420 gttgctgaaa ttaactcttt gtacgacgtt tacttagatg ttcaacagaa atggcacttg 480 aacgacgtca tgttgatggg tgactttaac gctgattgct cttatgttac ttcttctcaa 540 tggtcttcaa ttagattgag aacatcttca actttccaat ggttaattcc tgattccgct 600 gataccactg ctactagtac caactgtgct tacgatagaa tcgttgttgc tggatcatta 660 ttgcaatctt ctgttgtccc aggttcagcg gcccctttcg atttccaagc tgcatatggt 720 ttgtctaatg aaatggcttt agccatttct gatcactacc cagttgaagt cacattgaca 780 taa 783 38f (2) INFORMATION FOR SEQ ID NO: 6:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Nucleotide sequence encoding the native bovine signal peptide sequence of the DNase I pre-protein nucleic acid sequence (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
atgagaggta ctagattgat gggtttgtta ttagctttgg ctggtttatt acaattaggt 60 ttgtct 66 (2) INFORMATION FOR SEQ ID NO: 7:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 78 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:Nucleotide sequence encoding the native bovine signal peptide sequence of the DNase I pre-protein and an additional signal peptidase cleavage site (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
atgagaggta ctagattgat gggtttgtta ttagctttgg ctggtttatt acaattaggt 60 ttgtctctcg agaagaga 78 (2) INFORMATION FOR SEQ ID NO: 8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 255 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Saccharomyces cerevi:siae (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
atgagatttc cttcaatttt tactgctgtt ttattcgcag catcctccgc attagctgct 60 38g ccagtcaaca ctacaacaga agatgaaacg gcacaaattc cggctgaagc tgtcatcggt 120 tactcagatt tagaagggga tttcgatgtt gctgttttgc cattttccaa cagcacaaat 180 aacgggttat tgtttataaa tactactatt gccagcattg ctgctaaaga agaaggggta 240 tctctcgaga agaga 255 (2) INFORMATION FOR SEQ ID NO: 9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
gcgcctcgag aagagattga agattgctgc tttcaacatt agaactttcg gtgaaactaa 60 aatgtctaac gc 72 (2) INFORMATION FOR SEQ ID NO: 10:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence:primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
cgatatcata tcttctgaca attctaacga tgtaagatgc caaagtagcg ttagacattt 60 tagattc 67 (2) INFORMATION FOR SEQ ID NO: 11:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
gtcagaagat atgatatcgt tttaattcaa gaagttagag actctcactt ggttgcagtt 60 ggtaaattg 69 I
38h (2) INFORMATION FOR SEQ ID NO: 12:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:
cgtagtggta agtgtttggg tcatcttggt tcaagtagtc taacaattta ccaactgcaa 60 cc 62 (2) INFORMATION FOR SEQ ID NO: 13:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:
ccaaacactt accactacgt tgtttctgaa ccattgggta gaaactctta caaagaaaga 60 tacttattct tg 72 (2) INFORMATION FOR SEQ ID NO: 14:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 72 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:
ccaaacactt accactacgt tgtttctgaa ccattgggta gaaactctta caaagaaaga 60 tacttattct tg 72 38i (2) INFORMATION FOR SEQ ID NO: 15:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
ggatacttac caatacgacg acggttgcga atcttgtggt aacgattctt tctccagaga 60 acc 63 (2) INFORMATION FOR SEQ ID NO: 16:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 68 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:
cgaactcttt aaccttggta gagtgtgatg agaatttaac aacagcaggt tctctggaga 60 aagaatcg 68 (2) INFORMATION FOR SEQ ID NO: 17:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 58 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:
ccaaggttaa agagttcgct atcgttgctt tgcattctgc tccttctgac gctgttgc 58 38j (2) INFORMATION FOR SEQ ID NO: 18:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:
gccatttctg ttgaacatct aagtaaacgt cgtacaaaga gttaatttca gcaacagcgt 60 cagaagg 67 (2) INFORMATION FOR SEQ ID NO: 19:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: :.9:
gatgttcaac agaaatggca cttgaacgac gtcatgttga tgggtgactt taacgctgat 60 tg 62 (2) INFORMATION FOR SEQ ID NO: 20:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 65 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:
gttctcaatc taattgaaga ccattgagaa gaagtaacat aagagcaatc agcgttaaag 60 tcacc 65 38k (2) INFORMATION FOR SEQ ID NO: 21:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 64 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Descriptions of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:
gtcttcaatt agattgagaa catcttcaac tttccaatgg ttaattcctg attccgctga 60 tacc 64 (2) INFORMATION FOR SEQ ID NO: 22:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 63 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:
agcaacaacg attctatcgt aagcacagtt ggtactagta gcagtggtat cagcggaatc 60 agg 63 (2) INFORMATION FOR SEQ ID NO: 23:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:
cgatagaatc gttgttgctg gatcattatt gcaatcttct ;ttgtcccag gttcagcggc 60 cc 62 (2) INFORMATION FOR SEQ ID NO: 24:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 66 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:
ggctaaagcc atttcattag acaaaccata tgcagcttgg aaatcgaaag gggccgctga 60 acctgg 66 (2) INFORMATION FOR SEQ ID NO: 25:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 54 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:
ctaatgaaat ggctttagcc atttctgatc actacccagt tgaagtcaca ttga 54 (2) INFORMATION FOR SEQ ID NO: 26:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:
cgcgtctaga gcggccgctt atgtcaatgt gacttcaact gg 42 38m (2) INFORMATION FOR SEQ ID NO: 27:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 73 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:
cgaaaaatga gaggtactag attgatgggt ttgttattag ctttggctgg tttattacaa 60 ttaggtttgt ctc 73 (2) INFORMATION FOR SEQ ID NO: 28:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 75 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Artificial Sequence (ix) FEATURE:
(D) OTHER INFORMATION: Description of Artificial Sequence::primer (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:
tcgagagaca aacctaattg taataaacca gccaaagcta ataacaaacc catcaatcta 60 gtacctctca ttttt 75 (2) INFORMATION FOR SEQ ID NO: 29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 938 (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (vi) ORIGINAL SOURCE:
(A) ORGANISM: Pichia pastoris (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:
agatctaaca tccaaagacg aaaggttgaa tgaaaccttt ttgccatccg acatccacag 60 gtccattctc acacataagt gccaaacgca acaggagggg atacactagc agcagaccgt 120 tgcaaacgca ggacctccac tcctcttctc ctcaacaccc acttttgcca tcgaaaaacc 180 agcccagtta ttgggcttga ttggagctcg ctcattccaa ttccttctat taggctacta 240 acaccatgac tttattagcc tgtctatcct ggcccccctg gcgaggttca tgtttgttta 300 tttccgaatg caacaagctc cgcattacac ccgaacatca ctccagatga gggctttctg 360 agtgtggggt caaatagttt catgttcccc aaatggccca aaactgacag tttaaacgct 420 gtcttggaac ctaatatgac aaaagcgtga tctcatccaa gatgaactaa gtttggttcg 480 ttgaaatgct aacggccagt tggtcaaaaa gaaacttcca aaagtcggca taccgtttgt 540 38n cttgtttggt attgattgac gaatgctcaa aaataatctc attaatgctt agcgcagtct 600 ctctatcgct tctgaacccc ggtgcacctg tgccgaaacg caaatgggga aacacccgct 660 ttttggatga ttatgcattg tctccacatt gtatgcttcc aagattctgg tgggaatact 720 gctgatagcc taacgttcat gatcaaaatt taactgttct aacccctact tgacagcaat 780 atataaacag aaggaagctg ccctgtctta aacctttttt tttatcatca ttattagctt 840 actttcataa ttgcgactgg ttccaattga caagcttttg attttaacga cttttaacga 900 caacttgaga agatcaaaaa acaactaatt attcgaaa 938
Claims (19)
1. A method of producing a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein purified in step (d), comprising the steps of (a) providing a vector comprising a nucleotide sequence that encodes a pre-protein, the pre-protein comprising the bovine pancreatic protein and a signal peptide, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that comprises nutrients and methanol, whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and d) purifying the bovine pancreatic protein from the growth medium.
2. The method according to claim 1, wherein the amino acid sequence of the bovine pancreatic protein is SEQ ID NO: 1.
3. The method according to claim 1, wherein the signal peptide further comprises a signal peptidase cleavage site which is located directly adjacent to the first amino acid of the bovine pancreatic protein.
4. The method according to claim 1, wherein the amino acid sequence of the expressed pre-protein is selected from the group consisting of SEQ ID NO: 2, SEQ
ID NO: 3, and SEQ ID NO: 4.
ID NO: 3, and SEQ ID NO: 4.
5. The method according to claim 1, wherein the nucleotide sequence encoding the bovine pancreatic protein is SEQ ID NO: 5.
6. The method according to claim 1, wherein the nucleotide sequence encoding the pre-protein consists of the nucleotide sequence encoding the signal peptide fused to the nucleotide sequence encoding the bovine pancreatic protein.
7. The method according claim 5, wherein the nucleotide sequence encoding the signal peptide is selected from the group consisting of SEQ ID NO: 6, SEQ
ID
NO: 7, and SEQ ID NO: 8.
ID
NO: 7, and SEQ ID NO: 8.
8. The method according to claim 1, wherein the nucleotide sequence encoding the pre-protein is operably linked to a promoter or promoter element.
9. The method according to claim 1, wherein the vector is a plasmid capable of being replicated as an episome in the methylotrophic yeast strain.
10. The method according to claim 1, characterised in that an artificial chromosome capable of being replicated in the methylotrophic yeast strain contains the vector.
11. The method according to claim 1, wherein a chromosome of the methylotrophic yeast strain contains the vector.
12. The method according to claim 1, wherein the methylotrophic yeast strain is Hansenula, Pichia, Candida or Torulopsis species.
13. The method according to claim 12, wherein the methylotrophic yeast strain is selected from the group consisting of Pichia pastoris, Hansenula polymorpha, Candida boidinii and Torulopsis glabrata.
14. A bovine pancreatic protein with a specific desoxyribonuclease I activity of at least 6,000 units per mg of protein-produced by the method of claim 1.
15. A kit containing a bovine pancreatic protein with a specific desoxyribonuclease activity of at least 6,000 units per mg of protein and a reaction buffer comprising a divalent cation.
16. The kit of claim 15, wherein the bovine pancreatic protein is dissolved in a storage buffer containing water, glycerol, a protease inhibitor, and a divalent cation, wherein the reaction buffer contains a divalent cation selected from the group consisting of Mg2+, Ca2+ and Mn2+.
17. The bovine pancreatic protein of claim 14, wherein the protein has a specific desoxyribonuclease I activity of about 6,000 to about 8,000 units per mg of protein.
18. A method of producing a bovine pancreatic protein comprising the steps of:
(a) providing a vector comprising a nucleotide sequence comprising the sequence of SEQ ID NO: 6 operably linked to the sequence of SEQ ID NO: 5 that encodes the bovine pancreatic protein of SEQ ID NO: 2, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that comprises nutrients and methanol whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium.
(a) providing a vector comprising a nucleotide sequence comprising the sequence of SEQ ID NO: 6 operably linked to the sequence of SEQ ID NO: 5 that encodes the bovine pancreatic protein of SEQ ID NO: 2, (b) transforming a methylotrophic yeast strain with the vector, (c) cultivating the transformed methylotrophic yeast strain in a growth medium that comprises nutrients and methanol whereby the methylotrophic yeast strain expresses and secretes the bovine pancreatic protein into the growth medium, and (d) purifying the bovine pancreatic protein from the growth medium.
19. The method of claim 18, wherein the signal peptide further comprises a signal peptidase cleavage site which is located directly adjacent to the first amino acid of the bovine pancreatic protein.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02028115 | 2002-12-18 | ||
EP02028115.0 | 2002-12-18 | ||
US43933503P | 2003-01-10 | 2003-01-10 | |
US60/439,335 | 2003-01-10 | ||
EP03001213 | 2003-01-20 | ||
EP03001213.2 | 2003-01-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2453948A1 CA2453948A1 (en) | 2004-06-18 |
CA2453948C true CA2453948C (en) | 2011-09-20 |
Family
ID=32600611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2453948A Expired - Lifetime CA2453948C (en) | 2002-12-18 | 2003-12-18 | Recombinant bovine pancreatic desoxyribonuclease i with high specific activity |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4006396B2 (en) |
CA (1) | CA2453948C (en) |
-
2003
- 2003-12-17 JP JP2003419939A patent/JP4006396B2/en not_active Expired - Lifetime
- 2003-12-18 CA CA2453948A patent/CA2453948C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP4006396B2 (en) | 2007-11-14 |
JP2004194657A (en) | 2004-07-15 |
CA2453948A1 (en) | 2004-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006291780B2 (en) | Cleavage of precursors of insulins by a variant of trypsin | |
US7666629B2 (en) | Method for producing recombinant trypsin | |
CA2352609C (en) | Expression of alkaline phosphatase in yeast | |
US6984505B2 (en) | Modified chitin-binding domain and use thereof | |
US7118901B2 (en) | Recombinant bovine pancreatic desoxyribonuclease I with high specific activity | |
CA2453948C (en) | Recombinant bovine pancreatic desoxyribonuclease i with high specific activity | |
EP1433842B1 (en) | Recombinant bovine pancreatic desoxyribonuclease I with high specific activity | |
EP1431387B1 (en) | Heat-labile desoxyribonculease I variants | |
US20050214899A1 (en) | Removal of N-terminal methionine from proteins by engineered methionine aminopeptidase | |
US20040248272A1 (en) | Heat-labile desoxyribonuclease I variants | |
CN109957028B (en) | Methods for increasing production of mature peptides of secreted proteins | |
JP3982866B2 (en) | Method for producing secreted Kex2 derivative | |
EP1334183B1 (en) | NOVEL SOLUBLE ENDOPROTEASES FOR THE i IN VITRO /i PROCESSING OF RECOMBINANT PROTEINS | |
WO2002031157A2 (en) | Shrimp alkaline phosphatase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20231218 |